The QualityStocks Daily Friday, June 4th, 2021

Today's Top 3 Investment Newsletters

QualityStocks(CVHSY) $5.9000 +237.14%

StocksEarning(INTI) $0.1180 +88.80%

StocksEarning(STCB) $0.4779 +40.56%

The QualityStocks Daily Stock List

Cellect Biotechnology (APOP)

StockMarketWatch, TraderPower, StreetInsider, MarketClub Analysis, TradersPro, QualityStocks, BUYINS.NET, Promotion Stock Secrets, Schaeffer's, Marketbeat.com, MarketBeat and Louis Navellier reported earlier on Cellect Biotechnology (APOP), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Cellect Biotechnology Ltd. (NASDAQ: APOP) (FRA: 2EBA) is a biotechnology firm that is focused on the provision of biomedical services. It conducts its business in Israel.

The firm has its headquarters in Kfar Saba, Israel and was founded in 1986 on August 4th by Nadir Askenasy, Shai Yarkoni and Kasbian Nuriel Chirich. Prior to its name change in July 2016, the firm was known as Cellect Biomed Ltd. It operates in the healthcare sector, under the biotech and pharma industry.

The company is party to collaborations with XNK therapeutics entailing the development of cell-based therapies from NK cells; with Cell2in Inc. to carry out scientific evaluations combining the FreShtracer identification technology with the ApoGraft. This identification technology monitors stem cell quality by using a fluorescent dye; and with the Technische Universität Dresden’s denovoMATRIX group, to carry out examinations on the tentative synergy between denovoMATRIX tech and ApoGraft in order to assess the collaborative development of regenerative medicine products.

The enterprise, which provides clinical research, regenerative medicine, disease management and stem cell transplantation services is also engaged in the development of a technology platform that selects stem cells to improve stem cell therapies and the safety of regenerative medicine, known as ApoGraft. Additionally, it also develops a kit for hematipoietic stem cell transplantation procedures known as ApoTainer.

The company recently announced that it would be entering into a strategic merger with Quoin Pharmaceuticals Inc. This move would not only beneficial to the company’s shareholders but also afford them the best path to maximize their investment while allowing them to reap the benefits of the continued development of its cell and gene therapy assets. This will help boost investments into the firm.

Cellect Biotechnology (APOP), closed Friday's trading session at $3.15, off by 3.9634%, on 339,123 volume with 1,288 trades. The average volume for the last 3 months is 2.117M and the stock's 52-week low/high is $1.64950001/$7.15000009.

Allied Energy (AGYP)

We reported earlier on Allied Energy (AGYP), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Allied Energy Corporation (OTC: AGYP) is a development firm that operates as an independent oil and gas exploration company.

The firm has its headquarters in Del Mar, California and was incorporated in 2003. Prior to its name change in November 2007, the firm was known as Allied Energy Group Inc. The firm provides midstream, upstream and oilfield services in the gas and oil sector and operates as part of the fuel oil and LP gas dealers’ industry.

Its gas and oil projects are located in Ohio’s Athens and Washington county; Colorado’s Morgan county; Texas’ Leon county and Oklahoma’s Rogers county. The company has seventy wells under development and about six thousand acres under lease.

In addition to this, the company is focused on manufacturing, selling and distributing soil enhancers and organic fertilizers under the Building a Better World Green brand, mainly in the Americas. Here, it operates in the consumer staples sector, under the wholesale-consumer staples sub-industry. These products are utilized in commercial agriculture to help produce grains, nuts, vegetables and organic fruits. They help improve plant growth and enrich the soil via biologically enabled nutrient delivery systems. The company generates revenues from countries like China, Brazil, Mexico and Canada.

The firm recently leased 300 acres which host five additional oil wells in Texas. This acquisition, which was concluded via an all-cash purchase, adds considerable value to the firm’s bottom line. The lease, which contains potential gas and oil reserves may increase the firm’s revenue if it’s successful in its exploration stage. This will be beneficial to the firm’s shareholders.

Allied Energy (AGYP), closed Friday's trading session at $0.2827, off by 0.807018%, on 150,279 volume with 66 trades. The average volume for the last 3 months is 424,415 and the stock's 52-week low/high is $0.0027/$0.709999978.

Cablevision Holding S.A. (CVHSY)

We reported earlier on Cablevision Holding S.A. (CVHSY), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Cablevision Holding S.A (OTC: CVHSY) is an investment holding firm that mainly operates in Argentina’s telecommunications industry. It is engaged in the provision of mobile communications, broadband and television cable services as well as the development of infrastructure.

The firm has its headquarters in Buenos Aires, Argentina and was founded in 2016 on September 9. It operates in the technology sector, under the technology hardware sub-industry and as part of the consulting services industry. The firm serves consumers across the globe.

The company operates through the financing and investment segments. The former segment is engaged in the provision of services like guarantees, promissory notes, long and short term loans and loans on foreign and national currency. On the other hand, the latter segment is involved in holding and investing in shares of firms that provide telecommunication and information technology services and products for leasing and selling. The majority of its revenue is generated from broadband, cable television and mobile and fixed telephone operations.

The enterprise provides demand video platform products, digital, basic and high-definition channels. It also offers datacenter, video and cloud computing solutions as well as high-speed modern internet services. Additionally, it provides mobile services, which include corporate e-mail, online streaming, SMS, MMS, content and applications download and voice communication services and is also involved in the sale of mobile communication devices like smart watches, modems mifi and handsets.

The company, which is focused on growing its consumer reach, is working on increasing its revenues and reducing its operating costs and expenses. This will help attract more investors to the firm.

Cablevision Holding S.A. (CVHSY), closed Friday's trading session at $5.9, up 237.1429%, on 3,225 volume with 9 trades. The average volume for the last 3 months is 3,950 and the stock's 52-week low/high is $1.54999995/$6.1999998.

Asarina Pharma AB (ASRPF)

We reported earlier on Asarina Pharma AB (ASRPF), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Asarina Pharma AB (OTC: ASRPF) (FRA: APS) is a biotech firm that is engaged in the research and development of pharmaceutical products, with a primary focus on women’s health.

The firm has its headquarters in Solna, Sweden and was founded in 2006 by Mingde Wang and Carl Torbjörn Bäckström. Prior to its name change in 2016, the firm was known as Umecrine Mood AB. It operates as part of the healthcare industry, under the biotech and pharma sub-industry and serves consumers in Denmark and Sweden.

The enterprise’s primary shareholders are the Foundation for Baltic and East European Studies and the Kurma Biofund. It carries out trials in Europe and develops therapies for neurological and menstrual disorders, allopregnanolonerelated stress and premenstrual dysphoric syndrome. The enterprise’s main goal is to provide a new therapy that is specifically designed for premenstrual dysphoric disorder.

The company’s product pipeline is made up of a drug formulation known as Sepranolone, which has been indicated for the treatment of premenstrual dysphoric disorder. The candidate, which is also known as UC1010, is currently undergoing a phase 2b clinical trial evaluating its effectiveness in treating premenstrual dysphoric disorder as well as another phase 2a clinical trial evaluating its efficaciousness in treating Tourette syndrome and menstrual migraines. The candidate inhibits the effects of the steroid known as allopregnanolone, which is known to cause premenstrual dysphoric disorder.

The firm recently received a convertible loan which will allow them to continue exploring Sepranolone’s potential in neurological ailments, including obsessive compulsive disorder. If the firm’s candidate is successful, it will not only help individuals who suffer from this disorder but also boost investments into the firm, which will in turn promote growth.

Asarina Pharma AB (ASRPF), closed Friday's trading session at $2.45, even for the day. The stock's 52-week low/high is $2.45/$2.45.

Cadeler A/S (CADLF)

We reported earlier on Cadeler A/S (CADLF), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Cadeler A/S (OTC: CADLF) (FRA: CA2) is a firm that operates in Denmark as an installation and offshore wind farm transportation contractor.

The firm has its headquarters in Copenhagen, Denmark and was incorporated in 2008. Prior to its name change in October 2020, the firm was known as Swire Blue Ocean A/S. It operates in the industrials sector, under the transportation and logistics sub-industry as part of the water transportation services industry. The firm serves consumers across the globe and operates as a Swire Pacific Offshore Operations Ltd subsidiary.

The company has a good reputation as a provider of high quality offshore support wind services, which positions it to offer prime level services to the industry. It is pursuing new levels of efficiency, which pushes the boundaries of the supply chain. Its goal is to enable and facilitate the global energy transition to a future built on offshore renewable energy.

The enterprise operates a pair of offshore jack up windfarm installation vessels under the Wind Osprey and Wind Orca, which assist in the delivery of commercial scale offshore wind projects in Northern Europe. Its vessels are suitable for actions like salvage assistance, crane support, accommodation, decommissioning, offshore construction, IMR/subsea construction, platforms and structures, maintenance of offshore wind turbine generators and substations/platform topsides or wind turbine generators as well as the installation and transport of offshore foundations.

The firm recently revealed its plans to expand its fleet by procuring two new build X-class vessels for maintenance, operation and installation services on offshore wind farms. This move helps to solidify and expand the firm’s position as industry leaders, which is bound to encourage more investments into the firm.

Cadeler A/S (CADLF), closed Friday's trading session at $3.703, up 1.33%. The stock's 52-week low/high is $2.82652497/$4.03999996.

Quanta, Inc. (QNTA)

QualityStocks, Small Cap Firm, StockHideout, OTCBB Journal and Broad Street reported earlier on Quanta, Inc. (QNTA), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Quanta, Inc. (OTC: QNTA) is an applied sciences firm that is focused on providing a technology platform which centers on growing energy levels in plant matter in order to enhance performance in the human body.

The company has its headquarters in Burbank, California and was incorporated in 2016, on April 28th by Eric Allen Rice. It operates as a pharmaceutical firm and utilizes quantum mechanics via its proprietary technology to boost bio-activity of targeted molecules. Its mission is to deliver better and more effective products to boost product effectiveness, decrease waste and facilitate more sustainable and healthier consumption.

The firm sells its products through wholesalers, which include grocery stores, fitness studios, pharmacies and physicians; at DTC sales at events and conventions and also directly to consumers through online orders from its online sites. It also provides its technology as a platform to product makers via distribution channels as well as consumer products. The enterprise is focused on enhancing elements that occur naturally, to develop sustainable and impactful healing solutions.

It recently merged with a private firm known as Medolife, which produces nutraceutical and pharmaceutical products, to become Medolife Rx. Inc. As its subsidiary, the company is also engaged in the manufacture and distribution of consumer wellness products in high-impact consumer areas like beauty, pain relief and general wellness. This merger presents both firms with the opportunity to elevate how their pharmaceutical and commercial products are manufactured and enhance their benefits, while reducing their chemical concentration.

Quanta, Inc. (QNTA), closed Friday's trading session at $0.0597, up 15.251%, on 5,894,670 volume with 222 trades. The average volume for the last 3 months is 8.559M and the stock's 52-week low/high is $0.014999999/$0.204999998.

Cell Source, Inc. (CLCS)

We reported earlier on Cell Source, Inc. (CLCS), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Cell Source, Inc. focuses on Next-Generation Immunotherapy – safer transplantation and more effective cancer treatment. A biotechnology enterprise, its emphasis is on developing cell therapy treatments based on the management of immune tolerance. The Company’s patented Veto cell technology is the centerpiece of treatment protocols that represent significant breakthroughs in immune system management – safe and selective “tolerizing” of immune response.

Established in 2011, Cell Source has its corporate headquarters in New York, New York. The Company’s shares trade on the OTC Markets Group’s OTCQB.

Cell Source’s technology focuses on one of the most fundamental challenges in the field of immunology. This is how to tune immune response so that it tolerates specific “desirable” foreign cells and tissue while continuing to attack all other potential threats.

Regarding its recent development history, in 2019, the production protocol was completed for Veto Cell human trials in the United States. Anti-viral Veto Cell protocol IND was approved by the Food and Drug Administration (FDA) – a Phase 1/2 trial began at MD Anderson; Interim preclinical data from Zelig Eshhar collaboration establishes optimal conditions for Veto T-cell transduction with CAR.

Cell Source’s areas of therapeutic focus include Allogeneic Bone Marrow Transplantation (BMT), Cancer, and Organ Transplants. They also include Non-Malignant Disease. The Company’s Veto cell protocols are overcoming allogeneic transplantation’s greatest challenges. These include the need to find donors, rejection, Graft vs. Host Disease, as well as life-threatening infections.

Pertaining to Cancer, Cell Source’s therapeutic approach to leukemia, lymphoma, as well as myeloma combines the cancer-targeting and killing of a CAR-T cell with the persistence of a Veto cell in a single T-cell. Therefore, this provides sustained protection from cancer relapse.

Concerning Organ Transplants, the Company’s safe organ transplantation approach uses Veto cells’ selective immune targeting to enable the transplant recipient’s immune system to permanently accept organs from partially-matched donors. Regarding Non-Malignant Disease (Type-1 Diabetes, Sickle-cell Anemia, Multiple Sclerosis), the Company’s direct approach uses BMT with Veto cells to permanently repair the patient’s immune system so that it will stop attacking healthy tissue.

Cell Source, Inc. (CLCS), closed Friday's trading session at $2.00, up 25.00%, on 39,140 volume with 40 trades. The average volume for the last 3 months is 7,369 and the stock's 52-week low/high is $0.649999976/$2.54999995.

Meso Numismatics, Inc. (MSSV)

We reported earlier on Meso Numismatics, Inc. (MSSV), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Meso Numismatics, Inc. is a technology and numismatic company specializing in the Meso Region, including Central America and the Caribbean. It has become the primary hub for rare, exquisite, and valuable inventory from the Meso Region and worldwide. The Company was previously known as Pure Hospitality Solutions, Inc. It changed its name to Meso Numismatics, Inc. as a result of its merger with Meso Numismatics, Corp. in September of 2018. Meso Numismatics has its head office in Boca Raton, Florida.

Meso Numismatics is the only Company in the Central American-Caribbean region that is an on-the-ground registered dealer with the Numismatic Guaranty Company (NGC) and the Paper Money Guaranty (PMG). The Company has a selection of rare inventory, and also has a specialized App for banknote recognition, available on Google Play and the Apple App Store. Meso continues to partner with some of the largest auction houses internationally for the sale of the Company’s rarer inventory.

Meso Numismatics was established in September 2016 by a group of devoted coin collectors and currency seekers from the Mesoamerica area - from Mexico to Panama. The Company specializes in this area of the region. Moreover, Meso also has inventory and clients from all over the world. Numismatics is the study or collection of currency. This includes coins, tokens, paper money, as well as related objects.

In September, Meso Numismatics announced that it has preliminarily completed the due diligence phase of the Green Pay acquisition and is now set to proceed with an audit of Green Pay to be performed by the Company’s independent registered accounting firm. According to Management, Meso’s counsel will soon begin preparing the definitive purchase agreement for the Green Pay acquisition.

Afterward, the expectation is that Meso Numismatics will issue shares of its Preferred Stock as an initial payment for the acquisition. Following that, its U.S. independent registered accounting firm will start to audit Green Pay’s financials, preparing them to be included in Meso’s SEC filings at some later date.

At present, Green Pay hosts 110 independent stores located around Central America; processes around $2.5M in monthly transactions among all of its users; and executes roughly 500,000 transactions per month. Green Pay also has approximately 400,000 monthly active users; and has about 650,000 registered credit cards representing multiple payment institutions around Central America.

Meso Numismatics, Inc. (MSSV), closed Friday's trading session at $0.1295, up 29.50%, on 42,513 volume with 7 trades. The average volume for the last 3 months is 50,423 and the stock's 52-week low/high is $0.0091/$0.347999989.

Humble Energy, Inc. (HUML)

We reported earlier on Humble Energy, Inc. (HUML), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Humble Energy, Inc. is an oil and gas production and exploration company listed on the OTC Markets. Natural gas is 85 percent of the Company’s production. Humble Energy also owns coal minerals. It owns coal minerals in fee simple title that are high BTU metallurgical quality coal. Additionally, Humble has Coking coal with a high Button nine plus that blends with lesser coals to make steel. Humble Energy has its head office in Paron, Arkansas.

It commenced operations as a private Texas Corporation in 1999 as Humble Petroleum, Inc. In May 2009, Humble Petroleum, Inc. bought Humble Energy, Inc. transferring ownership interests in 83 wells in Texas, Wyoming, New Mexico, Kansas and Oklahoma. The wells purchased 85 percent of the common stock in Humble Energy, Inc. On December 30, 2013, Humble Petroleum, Inc. transferred the remaining assets of Humble Petroleum, Inc. that included oil and natural gas wells, coal, ATTI, and Power Klean. Humble Petroleum, Inc. common shares became Humble Energy, Inc. shares.

Currently, Humble Energy is participating in drilling 10 wells in the prolific Cotton Valley sand formation in Louisiana. The first 9 horizontal wells came in at 108,000,000 cubic feet per day on a 44/64 choke. Because of the successful results of the first 9 wells Humble has agreed to participate in the drilling of 4 more Cotton Valley formation wells.

Furthermore, the Company is participating in the drilling of 7 more wells in the Haynesville shale formation. Twenty more total wells will be drilled. Moreover, Humble has participated in drilling and completing producing horizontal wells in Kingfisher County, Oklahoma. The Company states that production to date has been excellent.

Humble Energy has its Power Klean product. Power Klean cleanses out contaminated motor oil. Tests show that the system removes greater than 85 percent of the harmful contaminates, wear metals, and carbon that typical oil changes miss. Features of Power Clean include lessening friction; extending engine life; increasing horsepower, and improving gas mileage. In addition, features include keeping oil cleaner for higher performance oil changes.

Humble Energy, Inc. (HUML), closed Friday's trading session at $0.61, up 22.00%, on 148,256 volume with 88 trades. The average volume for the last 3 months is 25,711 and the stock's 52-week low/high is $0.119999997/$7.9499998.

Windtree Therapeutics, Inc. (WINT)

TraderPower, QualityStocks, MarketBeat, StockMarketWatch, StreetInsider and MarketClub Analysis reported earlier on Windtree Therapeutics, Inc. (WINT), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Windtree Therapeutics, Inc. is a clinical-stage, biopharmaceutical and medical device company listed on the OTC Markets’ OTCQB. The Company focuses on the development of novel therapeutics intended to address significant unmet medical needs in important acute care markets. Windtree has four programs in clinical development and numerous pre-clinical programs that span respiratory and cardiovascular disease states. Windtree Therapeutics is headquartered in Warrington, Pennsylvania.

Three of the Company’s clinical programs are in late-stage development. They include AEROSURF®, a unique combination drug/device product candidate designed to deliver Windtree's proprietary synthetic, peptide-containing surfactant non-invasively to premature infants with respiratory distress syndrome (RDS).

Windtree also has its istaroxime, a novel, dual-acting agent undergoing development to improve cardiac function in patients with acute heart failure while avoiding the unwanted side effects of existing treatments. The Company also has its rostafuroxin, a novel precision drug product undergoing development to target hypertensive patients with certain genetic profiles in the important group of patients with resistant hypertension.

Furthermore, Windtree Therapeutics has manifold pre-clinical products. This includes potential heart failure therapies delivered orally that are founded on SERCA2a mechanism of action.

Previously, Windtree Therapeutics and CVie Investments Limited, together with its wholly-owned subsidiary, CVie Therapeutics Limited, a privately-held company centered on developing drugs to treat cardiovascular diseases, announced the closing of a definitive agreement for the merger of a Windtree Therapeutics subsidiary and CVie in an all-stock transaction. The combined company retains the name Windtree Therapeutics. It will be a fully-integrated and diversified acute care company with mid-to-late clinical stage product assets and multiple preclinical assets and programs. Led by Windtree management, the merged company will continue to be based in Warrington, Pennsylvania, with pre-clinical operations in Taipei, Taiwan, and Milan, Italy.

Recently, Windtree announced it had enrolled the first patient into its AEROSURF® phase 2b bridging study in premature infants with respiratory distress syndrome (RDS). This bridging study is intended to complete the phase 2 clinical program for AEROSURF and transition clinical development to phase 3 by validating the performance of the new aerosol delivery system (ADS) in the neonatal intensive care unit (NICU) and a more intensive dosing regimen.

Windtree Therapeutics, Inc. (WINT), closed Friday's trading session at $2.70, up 36.3636%, on 139,876,742 volume with 364,380 trades. The average volume for the last 3 months is 762,992 and the stock's 52-week low/high is $1.58010005/$10.0600004.

Nutriband, Inc. (NTRB)

We reported earlier on Nutriband, Inc. (NTRB), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

OTCQB-listed, Nutriband, Inc. chiefly engages in the development of a portfolio of transdermal pharmaceutical products. The Company’s lead product under development is its abuse deterrent fentanyl transdermal system. Nutriband’s mission is to use Transdermal Technology to improve patient comfort and efficacy and to take existing transdermal treatments and replace them with safer new alternatives. A Nevada Corporation, Nutriband has its corporate office in Orlando, Florida.

The Company is developing the abuse deterrent fentanyl transdermal system to provide clinicians and patients with an extended-release transdermal fentanyl product for use in managing chronic pain requiring around the clock opioid therapy combined with properties designed to help fight the opioid crisis through deterring the abuse and misuse of fentanyl patches.

A key Nutriband emphasis and area of expertise is in the development of transdermal products for currently injected compounds. This includes proteins, peptides, macromolecules, as well as biologics. Nutriband has capabilities for developing pharmaceutical products from pre-clinical testing to clinical manufacturing and early stage clinical development (Phase I/II).

Nutriband previously announced that the Japan Patent Office granted complete patent protection for the Japanese Patent Application entitled, "Abuse and Misuse Deterrent Transdermal System" submitted by its subsidiary, 4P Therapeutics. The patent relates to the Company's proprietary abuse deterrent transdermal technology, utilized in the fentanyl transdermal system that is undergoing development at 4P Therapeutics to battle the opioid epidemic. The news follows the March 2019 decision by the European Patent Office to grant European Patent Protection on the same technology.

4P Therapeutics (Corners, Georgia) is a wholly-owned subsidiary of Nutriband Inc. 4P’s focus is on the research and development (R&D) of novel drug delivery technologies and therapeutics. 4P Therapeutics develops products that meet the needs of patients, physicians, and also payers. 4P Therapeutics has developed the Defent™ abuse deterrent patch technology to deter abuse of fentanyl patches via the oral, buccal and inhaled routes that represent as much as 70 percent of all transdermal fentanyl abuse.

Nutriband, Inc. (NTRB), closed Friday's trading session at $14.99, up 24.9167%, on 309 volume with 5 trades. The average volume for the last 3 months is 241 and the stock's 52-week low/high is $1.00/$32.00.

DSG Global,  Inc. (DSGT)

QualityStocks, RedChip, Pennystockmania, StockHideout, Innovative Marketing, Epic Stock Picks, PennyDoctor, Penny Stocks Finder, Penny Stock Craze, PennyPickGains, OTC Markets Group, InvestorSoup, eliteotc.com, DSR News, Damn Good Penny Picks, Penny Picks, Beacon Equity Research, PHUB News, Wolf of Penny Stocks, ResearchOTC, SMS Penny Picks, Stock Preacher, StockRockandRoll, SuperStockTips, The Observer, Wall Street Beauties, Wallstreet Profiler, WINNINGOTC and PennyStockLocks.com reported earlier on DSG Global,  Inc. (DSGT), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

DSG Global,  Inc. is a technology development company whose shares trade on the OTCQB. The Company engages in the design, manufacture, and marketing of fleet management solutions for the golf industry, and also commercial, government, and military applications worldwide.  DSG Global has historically concentrated on the golf industry. It has grown to become a leader in the Fleet Management category in the golf industry.  DSG Global is based in Surrey, British Columbia.

The Company provides patented electronic tracking systems and fleet management solutions to golf courses. These allow for remote management of the course's fleet of golf carts, turf equipment, as well as utility vehicles. DSG is best known for its advanced GPS TAG System for golf cart and turf equipment fleet management. 

DSG Global’s technology is installed in more than 10,000 vehicles on golf courses globally. The Company has an installed base of daily-fee and resort golf courses. Its cart-mounted Touch® display screens seamlessly deliver banner advertisements and full-motion videos while on the golf course. 

Fundamentally, golf course operators manage their fleet of golf carts, turf equipment, and utility vehicles remotely, using DSG Global’s SaaS  (Software as a Service)  technology and advanced GPS hardware. DSG has acquired Impact Tournament Solutions, along with Impact’s team of experts, to run the Tournament Solutions Division of DSG Global. 

DSG Global is currently branching into several new streams of revenue via programmatic advertising, licensing, and distribution.  Additionally, the Company is expanding into Commercial Fleet Management and Agricultural applications. It realized record European sales in 2017 because of new installation contracts with top rated European Golf Management businesses. Furthermore,  DSG Global is expanding into Raptor Single Rider Golf Car and 100E Fully Loaded Mullen Golf Cars, 2 and 4 seaters and Agricultural applications.

DSG Global has officially partnered with golf course video flyover company, STEADY MOTION. This is to bring the best interactive flyover videos to the golf sports industry. These flyover videos include professional, broadcast television quality audio narration, advanced color correction, and interactive course tours ready to be displayed on the DSG TOUCH screens and on golf course web portals. 

The company was pleased recently to announce the Grand Opening of the Experience Center in Fairfield, CA. The tentatively scheduled Grand Opening (subject to COVID19 restrictions) will run from June 18 to June 19. At the Grand Opening the audience will be able to view many of the twenty-six (26) models the company sells. Additionally, the company will begin accepting in-person orders.

The company is also one of the few finalists for a one hundred (100) bus order for the city of Kiev, Ukraine valued at 18.3 Million Euro/$22 Million USD. The application process for qualified bidders is no longer open and Imperium Motors was selected as one of the few qualified applicants chosen from the bidders. It is anticipated this contract will be awarded during the month of June.

DSG Global,  Inc. (DSGT), closed Friday's trading session at $0.23, up 21.0526%, on 1,416,787 volume with 213 trades. The average volume for the last 3 months is 1.104M and the stock's 52-week low/high is $0.0108/$1.51999998.

Featured Whitepapers

A Case for Small & Micro-Cap Investing

Avenel Financial Group’s (AFG) financial research analysts and interns researched the top performing Microcap investors, studied their investments, and analyzed quantitative and qualitative metrics along with the historical performance of this asset class.

Read More...

Featured Whitepaper

XPEL Case Study

Did You Miss Your Opportunity on This 100-Bagger?

As a continuation of our study of Super Compounders we will evaluate one of the more prominent 100-Baggers of the past decade. XPEL technologies is a company that has rose to dominate the niche space of protective films for car paint and has rapidly grown through intelligent capital allocation and acquisitions. Paul Andreola of Smallcap Discoveries first brought this to MicroCapClub in 2013. Attached is an in-depth analysis of its meteoric rise, which we hope will help you to spot the next 100-Bagger.

Read More...

Featured Whitepaper

Quality Shareholders

Lawrence A. Cunningham discussed the makeup of the modern shareholder group in his recent book “Quality Shareholders.” In this paper we briefly discuss the primary takeaways and applications of the concepts in this book and the advantages inherent in the active cultivation of a quality, engaged shareholder cohort. The insights in Cunningham’s book are impactful and may illuminate new strategies for evaluating a firms management.

Managers get the shareholders they deserve.” – Lawrence Cunningham

Read More...

 

The QualityStocks Company Corner

Net Element (NASDAQ: NETE)

The QualityStocks Daily Newsletter would like to spotlight Net Element (NETE).

In a bid to reduce its reliance on fossil fuels and cut down on carbon emissions from the transportation sector, the United Kingdom will prohibit the sale of new petrol and diesel cars by 2030. The ban had initially been set for 2040, but under Prime Minister Borris Johnson’s new green plan, the ban was moved up to 2030, with car manufacturers being allowed to sell hybrid vehicles until 2035. With the ban on fossil fuel-powered vehicles fast approaching, new research has found out that one in four UK households plan on buying an electric vehicle (“EV”) within the next five years. The involvement of players such as Net Element (NASDAQ: NETE) that are traditionally from other sectors is likely to accelerate EV adoption even more in regions such as North America, given that those companies come with diverse experience that can be tapped to promote vehicle electrification.

On June 15, 2020, Net Element announced its entry into a binding letter of intent to merge with privately-held Mullen Technologies Inc., a Southern California-based electric vehicle company, in a stock-for-stock reverse merger in which Mullen’s stockholders will receive the majority of the outstanding stock in the post-merger company. The proposed merger is currently pending the execution of a definitive agreement, shareholder vote and regulatory approval.

Net Element Inc. (NASDAQ: NETE) is a global financial technology and value-added solutions group that supports electronic payments acceptance in an omni-channel environment spanning across point-of-sale, e-commerce and mobile devices. The company operates a payments-as-a-service transactional model and value-added services platform for small to medium enterprises in the U.S. and selected emerging markets.

Net Element believes the future of global commerce is being revolutionized as consumers quickly migrate toward omni-channel shopping utilizing mobile devices, desktop, and online services. The company’s all-in-one payment solutions support and unify a whole range of applications through a single, robust platform, allowing global onboarding and support for multiple payment methods.

Net Element has also launched a blockchain-focused business unit that will develop and deploy blockchain technology-based solutions. Net Element expects the new division to create a decentralized crypto-based ecosystem that will act as a framework for an unlimited number of value-added services, connecting merchants and consumers in a seamless, economically efficient transaction. This new business unit intends to also identify and invest in unique projects that decentralize and disrupt the payment processing industry by combining blockchain technology and real-world applications with talented development teams, strong fundamentals and addressable markets large in size.

“We believe that we’re at the dawn of a new evolution where additional digital payment methods are being introduced,” Net Element chairman and CEO Oleg Firer, says. “Introduction of our division focused on blockchain as part of the NASDAQ-listed entity will add transparency and compliance assurance to our investors as well as provide access to deploy value-added services to over 20 million electronic commerce clients that are currently part of Net Element’s growing network.”

Net Element clients are treated to customized solutions that provide the flexibility needed to keep up with customers. Among the services offered are mobile payment apps that accept payments anywhere, anytime; cloud-based solutions built to increase productivity and enhance revenue for clients and partners; marketing solutions that turn lookers into buyers; and business analytics that make it easy for clients to monitor business metrics, engage with customers and compare the competition. Its multi-channel platform combines e-commerce, offline, point-of-sale, comprehensive back office tools, mobile point-of-sale, credit scoring and customer interaction in one powerful platform-as-a-service technology.

Net Element owns and operates a global mobile payments and transactional processing provider, TOT Group, Inc., with the following subsidiaries:

  • Unified Payments – An award-winning, customized mobile billing and payments solution, recognized by Inc. Magazine as the No. 1 Fastest Growing Company in America in 2012.
  • Aptito – A next-generation, all-in-one, cloud-based restaurant management and point-of-sale payments platform using wireless technology.
  • Payonline – A fully integrated, processor agnostic electronic commerce platform.

Net Element is ranked on Deloitte’s Technology Fast 500™ list of North America’s 500 fastest growing technology, media, telecommunications, life sciences and energy tech companies in both 2017 and 2018, during which the company grew 190 percent and 183 percent, respectively. The company credits its progression to organic growth in its North America Transactions Segment, specifically the success of its Unified Payments brand, which focuses on value-added payment acceptance solutions for small to medium enterprises in the United States.

Net Element was also listed among South Florida Business Journal’s 2016 fastest growing technology companies.

Leveraging its suite of application performing interfaces (APIs) and connectors, Net Element powers commerce for businesses of all sizes through multi-channel platforms, all-in-one digital solutions, and end-to-end encryption of cardholder data utilizing tamper resistant hardware that ensures integrity and simplifies security.

Leading this innovation is chairman and CEO Oleg Firer, who is responsible for the overall vision, strategy and execution of the company’s mission of powering global commerce. He is joined by CFO Jeffrey Ginsburg, CPA, and Steven Wolberg, the company’s chief legal officer and secretary. Each corporate officer brings a unique blend of leadership, vision, experience and creative energy to the company.

From mobile payments and value-added transactional innovations like Aptito to e-commerce and retail payment transaction processing brands like Payonline and Unified Payments, Net Element is transforming the online and mobile experience.

Net Element (NETE), closed Friday's trading session at $10.83, up 4.4359%, on 81,689 volume with 697 trades. The average volume for the last 3 months is 269,609 and the stock's 52-week low/high is $2.33999991/$20.0783996.

Recent News

SRAX Inc. (NASDAQ: SRAX)

The QualityStocks Daily Newsletter would like to spotlight SRAX Inc. (NASDAQ: SRAX).

InvestorBrandNetwork (“IBN”), an innovative corporate communications agency and diversified content distributor, recently announced that it will be collaborating with SRAX (NASDAQ: SRAX) subsidiary LD Micro for the upcoming LD Micro Invitational XI - an entirely digital three-day investor conference taking place June 8-10, 2021, on SRAX’s Sequire investor analytics SaaS platform (https://ibn.fm/3Vsof).

SRAX Inc.'s (NASDAQ: SRAX) is a digital marketing and consumer data management technology company. SRAX’s technology unlocks data to reveal brands’ core consumers and their characteristics across marketing channels.

Through its BIGtoken platform, SRAX has developed a consumer-managed data marketplace where people can own and earn from their data, thereby providing everyone in the internet ecosystem choice, transparency and compensation.

SRAX’s tools deliver a digital competitive advantage for brands in the CPG, automotive, investor relations, luxury and lifestyle verticals by integrating all aspects of the advertising experience, including verified consumer participation, into one platform.

SRAX Verticals

  • SRAX Core: SRAX Core is a custom digital media management platform that enables brands and agencies to surpass the challenges of omnichannel marketing campaigns. It offers one comprehensive dashboard to manage digital media campaigns, inventory and reporting.
  • SRAX Social: SRAX Social is a free social media management tool that makes it easy for brands, agencies and individuals to grow their digital presence. It offers free and unlimited users, Facebook auto boosting, and a custom analytics dashboard. Its managed services team can also build and execute marketing plans for your unique specific needs.
  • SRAX IR: SRAX IR unlocks stock buyers’ behaviors and trends for issuers of publicly traded companies. The platform provides insights on shareholders and market makers, investor relations management, shareholder outreach tools and data-driven marketing.
  • SRAX Auto: SRAX Auto unlocks auto intenders’ data to create measurable connected experiences on the road to purchase. It offers proprietary auto intender profiles, multi touchpoint communication and custom location-based ads.
  • SRAX Shopper: SRAX Shopper delivers a cross channel, premium digital experience at scale to high value shopper audiences. It offers proprietary shopper profiles, cost per click pricing, and custom text and add to cart ad units.
  • SRAX Lux: Launched in June 2019, the SRAX Lux platform targets and reaches luxury consumers at luxury retail stores, high-end art, music, film, fashion and sports events, across all consumer devices.

BIGtoken

BIGtoken, available for download on the App Store and Google Play, revolutionizes data collection. BIGtoken is a platform that creates a secure and transparent environment for consumers to own and earn from their data. To date, there are 15.9 million BIGtoken registered users worldwide.

The optimization and monetization of data is a multibillion-dollar business. Worldwide spending on big data and business analytics solutions reached $166 billion in 2018 and is projected to surge to $260 billion by 2022. BIGtoken’s consumer vision is committed to delivering choice, transparency and compensation to the individual.

Through BIGtoken, consumers earn rewards when they opt into sharing their data and when that data is purchased. Consumers decide what data is shared, who can buy it and how it’s used, and advertisers reach real, responsive audiences. The benefit of this is two-fold: consumers know how their data is used and advertisers gain verified consumer data for targeting.

Users of the BIGtoken app can officially be paid in cash or gift cards in exchange for giving brands access to their anonymized data, answering questions, checking into locations, recruiting new members, and more. Users can deposit their earnings directly into PayPal accounts or be paid through gift cards from favorite retailers such as Walmart.

SRAX has also partnered with several high-profile, nonprofit associations to provide BIGtoken users the ability to donate their earnings. Partnerships include the American Heart Association, dedicated to fighting heart disease and stroke; HealthCorps, which helps high school students make better choices about health and physical fitness; and the ALS Association, which recently launched its Challenge Me campaign.

International Expansion

BIGtoken is formally launching into several international markets and partnering to foster local support. SRAX recently signed a joint venture with the Yash Birla Group to launch BIGtoken in India. Based in Mumbai, the Yash Birla Group, one of India’s largest conglomerates, has diversified interests in consumer and industrial products.

The partnership will bring BIGtoken’s platform to India, which has a digital population of 627 million. The India digital advertising market is $3.6 billion and is set to grow at a compound annual growth rate of 32%, making it one of the largest growing digital ad markets in the world.

SRAX Mexico is led by Moe Avitia, who has more than 18 years of experience in business development and building high-tech teams. SRAX Mexico includes a team of 90 employees, including 70 engineers.

BIGtoken Europe is currently evaluating data centers in individual countries for privacy laws.

Leadership

Christopher Miglino is CEO and founder of SRAX. He has spent the past 20 years working in the digital advertising space and has successfully launched and sold two internet companies. Both of these companies were sold to publicly traded companies on the NASDAQ. He has a detailed understanding of how technology interacts with brands.

Kristoffer Nelson is COO of SRAX and a founding member of BIGtoken. With over 15 years of technology and creative business experience, Nelson has been a guest speaker for Loyola Marymount University among other academic institutions, the National Association of Broadcasters, the IAB and numerous other professional and media organizations.

SRAX Inc. (NASDAQ: SRAX), closed Friday's trading session at $5.51, up 2.7985%, on 549,635 volume with 2,899 trades. The average volume for the last 3 months is 702,720 and the stock's 52-week low/high is $1.77610003/$7.19500017.

Recent News

AmpliTech Group Inc. (NASDAQ: AMPG)

The QualityStocks Daily Newsletter would like to spotlight AmpliTech Group Inc. (NASDAQ: AMPG) (NASDAQ: AMPGW).

AmpliTech Group (NASDAQ: AMPG), a designer, developer and manufacturer of custom and standard state-of-the-art RF components, recently received a significant development order. Amplify My Probe Ltd., a company that specializes in commercializing technology to improve the signal-to-noise ratio in Electron Paramagnetic Resonance (“EPR”) experiments, placed the order for a special cryogenic probe head used to facilitate studies on materials, molecules and drugs to treat diseases, among other applications. “AmpliTech will leverage its proprietary low-noise amplifier technology that operates at 5 degrees Kelvin (-450 degrees Fahrenheit) to create the requested probe,” a recent article noted. According to Amplify My Probe’s Dr. Simenas Mantas, the device is expected to significantly speed EPR experiments (by an anticipated 100x increase in speed) through amplifying microwave signals and suppressing source noise. Dr. Mantas was quoted as saying, “Such an improvement is highly relevant in the field as it will significantly expand the domain of systems that can be studied by EPR.” To view the full article, visit https://ibn.fm/HQb8K

AmpliTech Group Inc. (NASDAQ: AMPG) (NASDAQ: AMPGW) designs, develops and manufactures custom radio frequency (RF) components for the commercial, SATCOM, space and military markets. In addition to developing new products for the 5G/6G wireless ecosystem and infrastructure, the company has placed focus on the development of leading-edge solutions in quantum computing in support of U.S. efforts to reach the coveted position of quantum supremacy. The company maintains a commitment to R&D that allows it to remain at the forefront of emerging technologies. AmpliTech aims to use its advanced techniques and IP to provide tomorrow’s technology today, improving everyone’s quality of life.

AmpliTech was founded by Fawad Maqbool in 2002 to fill the need for affordable, high-quality, customized and state-of-the-art amplifiers and components. Headquartered in Bohemia, New York, the company currently has distributors and representatives available worldwide.

Product Portfolio

AmpliTech’s mission is to develop quality, state-of-the-art microwave amplifiers by leveraging its experience, proven technical expertise and superior design heritage. The company’s products cover a frequency range from 50 kHz to 44 GHz, with plans to eventually offer designs up to 100 GHz. Its current catalog includes:

Amplifiers

Passive Components

All the company’s products come with a satisfaction guarantee, as the company is fully committed to providing only high-quality products free from manufacturing and material defects and guaranteed to perform according to applicable specifications.

Consulting Services

Leveraging more than 100 years of combined experience in microwave systems and component design ranging from active components to passive devices, AmpliTech also provides valuable consulting services and technical assistance to its customers.

With capabilities ranging from initial design to final manufacturing and delivery, the company’s team also offers project management services and advice on both technical aspects and how to handle business issues such as resource allocation, customer contact, budget restraints, time limits and more.

Other key benefits of AmpliTech consulting services that can give its customers a definitive edge include:

  • Timely technical assistance
  • Little or no learning curve
  • Less long-term costs associated with full-time employees with benefits and salaries
  • Availability when necessary
  • Customer support with schedules, project management and on the job training
  • Access to technology
  • Partnering for manufacturing and/or complete turn-key product solution
  • Personal guidance from concept to development
  • Custom designs for each application

Market Outlook

The global microwave devices market was valued at $7.44 billion in 2019 and is expected to grow at a CAGR of 3.23% and reach $9 billion by 2025 (https://nnw.fm/zqMEk). Governmental expenditures in the defense and space communications sectors are expected to expand the opportunities for growth within the industry.

AmpliTech continues to follow its strategy of identifying key elements in today’s technological revolution. It is leveraging its technical expertise and experience to align product portfolios and IP with innovation (https://nnw.fm/rVzxX). The company has plans to be a catalyst in the enhancement, development and distribution of breakthroughs in the following sizeable markets:

  • High Speed Terrestrial and Satellite Terminals (SATCOM, “Internet in the Sky”)
  • 5G/Wi-Fi6E and 6G wireless infrastructure (Cellular Base Stations, Small Cells, Private Wi-Fi Networks)
  • IoT (Internet of Things)
  • Cloud Farms, Big Data and MEC architecture
  • Quantum Supercomputers/Quantum Research
  • Deep Space Astronomy
  • Autonomous Self-Driving Vehicles
  • Telemedicine, AR/VR (Augmented and Virtual Reality)
  • Drones, UAVs (Unmanned Aerial Vehicles)
  • Cyber-security
  • Military/Defense ECM/EW

Management Team

Fawad Maqbool is the Founder, President, CEO and CTO of AmpliTech Group Inc. He has been in the microwave industry for over 30 years. Mr. Maqbool spent 14 years developing state-of-the-art amplifiers and components for MITEQ Inc., a leading microwave and communications equipment supplier. He founded AmpliComm in 2000, which was subsequently acquired by Aeroflex Inc. Mr. Maqbool has management and design experience, which has led to the development of microwave technology on a commercial and military level. He holds a B.S.E.E in Microwave Engineering and a B.S.E.E in Bio-Medical Engineering from CUNY and an M.S.E.E from the Polytechnic University of New York.

Louisa Sanfratello is the company’s CFO. She is a Certified Public Accountant (CPA) and has worked in various industries since 1998. During this time, she held roles as an accountant for charities and schools, consisting of the preparation of official financial documents and day-to-day financial management requirements. Ms. Sanfratello began her professional career in 1987 at Holtz, Rubinstein & Co., a public accounting firm. She gathered two years of experience there before gaining her CPA and taking on more challenging roles.

Brandon Worster is the company’s Director of Engineering. He joined AmpliTech at the end of 2019, bringing over 14 years of design and management experience. His specialty is Low Noise and Medium Power Amplifiers, but Mr. Worster also has vast experience with various systems, including RF/Microwave devices and systems. He holds a master’s degree in electrical engineering and is an adjunct professor at Farmingdale University in New York.

John P. Pastore is AmpliTech’s Director of Sales. He has worked in the microwave industry for more than 35 years, including time with some of the industry’s leading names. Mr. Pastore is a hands-on professional who has experience that spans over 20 years with progressive roles that blend technical, manufacturing, customer service and management expertise. He is an extremely valuable asset to the company as it moves forward due to his business savvy approach and deep industry knowledge. He has a B.S. in Business Management.

M. Syed handles Technical Sales and is the company’s Director of IT. He is an electrical engineer with more than 10 years of business experience. Since 2011, he has led Technical Sales for AmpliTech, and he recently became the President and CEO of his own company while also serving as Chief Technical Sales consultant for numerous other companies and groups in New York City. Mr. Syed has been in the IT industry for 25 years. He is a Computer Engineer by trade and a Certified Netware Engineer and Microsoft Certified Systems Engineer.

AmpliTech Group Inc. (AMPG), closed Friday's trading session at $5.24, up 13.1749%, on 494,865 volume with 2,923 trades. The average volume for the last 3 months is 863,884 and the stock's 52-week low/high is $0.564999997/$19.7999992.

Recent News

Infobird Co., Ltd (NASDAQ: IFBD)

The QualityStocks Daily Newsletter would like to spotlight Infobird Co., Ltd (NASDAQ: IFBD).

Infobird (NASDAQ: IFBD), a Software-as-a-Service (“SaaS”) company offering artificial intelligence (“AI”)-enabled end-to-end customer engagement solutions in China, has always held that the growth of China’s intelligent customer service industry as a whole can only be realized through the dint of cooperation. In a 2020 blog article published on its website (https://ibn.fm/Ixhii), Infobird delineated why it is crucial for upstream manufacturers, midstream technology and product service providers, and downstream system integrators to build a healthy ecology.

Infobird Software (NASDAQ: IFBD), a software-as-a-service (“SaaS”) provider of AI-powered customer engagement solutions in China, offers holistic software solutions to support its growing corporate clientele deliver and manage customer engagement activities from beginning to end of the sales process; the company’s services even extend beyond to pre-sales and post-sales client support and involvement. Infobird combines its proprietary cloud computer structure with patented Voice over Internet Protocol (“VoIP”) and AI and machine learning capabilities as well as a no-code development platform for a flagship customer engagement offering unlike anything else in the industry. For more information, visit the company’s website at www.Infobird.com

Infobird Co., Ltd (NASDAQ: IFBD) is a software-as-a-service (SaaS) provider of AI-powered customer engagement solutions in China. Infobird leverages a self-developed cloud computing structure, AI and machine learning capabilities, patented Voice over Internet Protocol (VoIP) application technologies, a no-code development platform and in-depth industry expertise to best serve its growing client base.

Founded in October 2001, Infobird empowers clients with value-driven business solutions designed to increase revenue, reduce costs and enhance service quality and customer satisfaction. The company currently specializes in corporate clients in finance and a broad array of ancillary industries.

Infobird is headquartered in Beijing, China, and began trading on the Nasdaq Capital Market on April 20, 2021, following an initial public offering of 6.25 million ordinary shares at a public offering price of $4.00 per share, before underwriting discounts and commissions.

Product Offering

Infobird’s flagship customer engagement software can handle both AI Customer Engagement and AI Salesforce Management.

  • AI Customer Engagement
    • Intelligent Omni-Channel Customer Service – This offering allows clients to connect with their customers anytime and anywhere through a comprehensive suite of cloud-based tools.
    • Cloud Call Center – This service puts Infobird’s years of technical and operational experience to work for clients, with options including intelligent IVR technology, call monitoring, routing strategy and ticketing systems, all supported by multi-dimensional data reports.
    • Intelligent Telemarketing – Infobird’s AI bots can help clients navigate “never-ending lists” of potential customers, filter out the most promising leads and increase the working efficiency of agents, keeping agents focused on high-value tasks.
    • AI Voice Chatbot and AI Text Chatbot – This technology allows clients to create human-like interactions offering 24/7 availability and multi-round dialogue capabilities, decreasing labor costs by up to 80% while greatly improving efficiency.
  • AI Salesforce Management
    • Intelligent Quality Inspection – Infobird’s platform aims to improve quality inspection rates and service levels through the use of real-time smart monitoring with comprehensive coverage.
    • Intelligent Training – Interactive training programs allow clients to ensure and continuously improve the performance level of their agents, lessening the impact of high turnover rates common throughout the customer service industry.

Infobird’s client base includes roughly 10,000 paid user accounts representing 358 customers in the industries of finance, education, public services, consumer products and health care – as reported on June 30, 2020.

Market Outlook

Cloud infrastructure services spending in China increased by 32% ($39.9 billion) in the fourth quarter of 2020. For all of 2020, total services grew to $142 billion, up from the reported $107 billion in 2019. This growth can be attributed to rising demand for cloud infrastructure over physical software solutions (https://ibn.fm/rHZUh). China is the second-largest market for cloud infrastructure solutions after the U.S., accounting for roughly 14% of the global industry.

Likewise, SaaS has demonstrated considerable growth potential in recent years. In 2020, the SaaS industry in China was valued at $3.3 billion, representing an increase of 43.5% over 2019, as companies continue to leverage artificial intelligence and Big Data technologies to increase efficiencies and promote expansion.

As one of the leading and longest standing providers of domestic SaaS solutions and with a comprehensive portfolio of intelligent, customizable and scalable solutions, Infobird is uniquely positioned to capitalize on the market’s expansion and resulting opportunities for corporate growth.

Management Team

Yimin Wu is the CEO and Founder of Infobird. He has served as the Chairman of the board of directors and Chief Executive Officer of the company since it was founded. From August 1990 to March 1993, Mr. Wu was a software engineer for the Software Center of Tsinghua University and was sent to the U.S. to co-develop the HP_UX operating system at HP Inc. From April 1993 to May 2000, he served as the general manager for Beijing Jing Zhou Computers Co. Ltd., a company responsible for marketing and developing interactive voice response systems. From July 2000 to October 2001, Mr. Wu was the general manager for Beijing Jing Zhou Rong Hua Internet Technology Co. Ltd, a company responsible for developing middleware for call center establishments. He received a bachelor’s degree and a master’s degree in computer sciences from Tsinghua University.

Hsiaochien Tseng is the EVP of Infobird and has held the title since January 2020. From March 2010 to September 2018, he served as a sales director for the Credit Card Center of China Guangfa Bank, where he was responsible for integrating and managing online and offline sales channels, establishing overall and regional sales strategies and creating training systems to increase the client base. From October 2018 to January 2020, Mr. Tseng served as SVP of Hua Tuo Digital Technology Group Co. Ltd., a financial information technology company. He received a bachelor’s degree in information management from Fu Jen Catholic University and a master’s degree in business administration from San Diego State University.

Chunhsiang Chen is the VP of Infobird, a position he has held since April 2012. From June 1990 to February 1993, he served as an advisory programmer of International Business Machine Corp. (IBM). During that time, he participated in the design and development of the Multiple Protocol Transport Network. From February 1993 to September 1996, Mr. Chen served as an associate professor in the Information Education Department of National Taiwan Normal University. He founded GenNet Technology Co. Ltd., an information technology company, in 1993 and served as the president until joining Infobird in 2012. Mr. Chen has a bachelor’s degree in computer sciences from the National Chiao Tung University and a master’s degree and doctoral degree in computer sciences from Northwestern University.

Lianfang Zhou is the CFO of Infobird and has been with the company for over 10 years. From September 2004 to July 2008, she served as the head of accounting at Beijing Saishuo Technology Co. Ltd., a software development company specializing in port services. From August 2008 to December 2009, Mrs. Zhou served as the head of accounting for Beijing Lianhe Lida Investment Co. Ltd., a property management services company. She holds an intermediate accounting qualification certificate issued by the Ministry of Finance of the PRC. Mrs. Zhou also has a bachelor’s degree in accounting from the Renmin University of China.

Infobird Co., Ltd (IFBD), closed Friday's trading session at $3.78, up 1.0695%, on 320,281 volume with 821 trades. The average volume for the last 3 months is 1.42M and the stock's 52-week low/high is $3.52399992/$11.25.

Recent News

Excellon Resources Inc. (TSX: EXN) (NYSE American: EXN) (FSE: E4X2)

The QualityStocks Daily Newsletter would like to spotlight Excellon Resources Inc. (TSX: EXN) (NYSE American: EXN) (FSE: E4X2).

Recent research conducted by S&P Global Market Intelligence has discovered that actual capital expenditures decreased by 8% last year in more than 400 mining companies. This was a result of the regional lockdowns imposed, which brought about work stoppages and placed unprecedented stress on international supply chains. At the start of last year, S&P Global Market Intelligence forecasted a capital expenditure of more than $160 million, based on a 9% year-over-year increase of the previous year. However, the pandemic’s impact on the mining sector prompted miners to alter spending plans, which brought the forecasted capital expenditures to about $155 billion. The pandemic’s effect on the sector only increased as the year progressed, which resulted in last year’s actual spending to total approximately $149 billion. These figures were 4% and 8% lower than COVID-19 revised and pre-COVID forecasts, respectively. All in all, as the pandemic is brought under control, the operations and capital spend of mining companies such as Excellon Resources Corp. (TSX: EXN) (NYSE American: EXN) (FSE: E4X2) can only scale greater heights.

Excellon Resources Inc. (TSX: EXN) (NYSE American: EXN) (FSE: E4X2) (“Excellon” or the “Company”) is a silver and base metals producer with precious metal exploration and development projects in Mexico, Idaho and Germany. Since being founded in 1987, the Company has been advancing a precious metals growth pipeline focused on creating wealth for its stakeholders by realizing strategic opportunities in the silver and gold markets.

Excellon is an active and influential member of the Mining Association of Canada (“MAC”). The Company implements a practical, best-in-class management system that addresses the safety, health, security, environmental and community aspects of its operations, per the UN Sustainable Development Goals. On each project, the Company incorporates MAC’s Towards Sustainable Mining Initiatives and other world-class best practices with the objective of constantly improving its safety systems, training and hazard recognition.

Precious Metals Growth Pipeline

The Company is advancing a precious metals growth pipeline that includes: Platosa, Mexico’s highest-grade silver mine since production commenced in 2005; Kilgore, a high-quality gold development project in Idaho with strong economics and significant growth and discovery potential; and an option on Silver City, a high-grade epithermal silver district in Saxony, Germany, with 750 years of mining history and no modern exploration.

Maintaining and developing this pipeline presents the Company with enhanced opportunities in the expanding precious metals market, which was valued at $193.3 billion worldwide in 2020 (https://nnw.fm/6nv5f). This market is expected to increase at a compound annual growth rate (“CAGR”) of 9% from 2020 to 2027, resulting in an estimated $362.1 billion market size in 2027 (https://nnw.fm/6nv5f). Global market demand was calculated at 22,581.8 tons in 2020 and is expected to grow to 36,501.1 tons in 2027, achieving a CAGR of 3.5% (https://nnw.fm/6nv5f).

Excellon reported strong results in terms of both production and average pricing at the end of Q4 2020, including:

  • Silver – 355,581 oz – $24.46
  • Lead – 2,223,465 lbs. – $0.87
  • Zinc – 2,452,728 lbs. – $1.21

Compared to Q4 2019, Excellon’s silver production increased by 37%, lead increased by 32% and zinc increased by 19% in Q4 2020 (https://nnw.fm/4C0P7).

Platosa Mine – Silver, Lead, Zinc – Production, Development & Exploration

The Platosa Mine is located 5 km north of Bermejillo, Durango, Mexico, on a 14,000-hectare property. The mine commenced production in 2005 as an underground operation and is 100% owned and operated by Excellon. The Company is mining massive sulfide ores rich in silver, lead and zinc from a series flat-lying massive sulfide bodies (mantos) in a carbonate replacement deposit system. Historically, the mining method was a modified room and pillar method, which transitioned to cut-and-fill in recent years and overhand-cut-and-bench in 2020. The ore produced from the mine is transported 200 km south for processing at the Company’s 100% owned Miguel Auza mill.

Kilgore Project – Gold – Exploration & Resource Growth

The Kilgore Project is located in Clark County, situated in eastern Idaho in the United States. The project area is 100% owned and operated by Excellon. While still in the exploration and development phase, the primary target on the 13,627-acre site is an epithermal gold system. The property itself has historical mining that dates back to the 1930s, with modern mineral exploration beginning in the 1980s. The Kilgore Project displays characteristics similar to Kinross Gold’s Round Mountain Mine, which has produced more than 15 million ounces of gold since operations began in 1977.

Evolución Project – Mineral Processing, Resource Growth & Exploration

The Evolución Project is located in Miguel Auza, Zacatecas, Mexico, and hosts a large gold, silver, lead and zinc epithermal within a 45,000-hectare property that is 100% owned by Excellon. The site includes a processing facility with a mill and flotation circuit which processes ore from Excellon’s Platosa mine. The facility has a capacity of 800 tons per day, with a 650 ton-per-day ball mill in operation and a second 150 ton-per-day ball mill on standby. Excellon is looking at opportunities for toll milling, expansion and economic study of the mineral resource and grassroots exploration. Importantly, the project covers an unexplored 35-kilometer strike of the Fresnillo silver trend, the richest silver belt in the world.

Silver City Project – Exploration

Excellon holds an option to acquire the 16,400-hectare Silver City Project in Saxony, Germany. Initial drilling results in 2020 confirmed the presence of a high-grade, district-scale epithermal silver system over more than 12 kilometers of strike. The Company is now focused on defining wider zones of mineralization (https://nnw.fm/jMah9). Silver City was mined from the 11th to late-19th century, until Germany moved off the silver standard in 1873. The deposits in the area were exceptionally high grade, with historical records indicating grades well in excess of 1,000 g/t silver.

Oakley Project – Exploration

The Oakley Project, located in Oakley, Idaho, is an exploration project with land holdings of approximately 7,000 acres. The project hosts gold-silver, epithermal hot spring-type mineralization at two targets: Blue Hill Creek and Cold Creek, and detachment-related gold-silver mineralization at Matrix Creek. The Company has granted Centerra (U.S.) Inc. an option to earn in to a 70% interest by, among other things, spending up to US$7 million in exploration expenditures on the project prior to May 2026.

Management Team

Brendan Cahill is the President & Chief Executive Officer of Excellon Resources Inc. He was previously Vice President Corporate Development of Pelangio Exploration Inc., a junior gold exploration company active in Ghana, West Africa. Mr. Cahill is a board member of the Mining Association of Canada, Group Eleven Resources Ltd., and Kore Mining Inc. He holds a law degree from the University of Western Ontario and an undergraduate degree from the University of Toronto.

Alfred Colas is the Company’s Chief Financial Officer. Most recently, he held the title of CFO of Arch Corp., a Toronto-based private-equity investment firm. Mr. Colas has over 18 years of experience in the mining industry. He is a sitting board member for a housing corporation affiliated with the University of Toronto and is a Chartered Professional Accountant. Mr. Colas completed a Bachelor of Commerce at the University of Toronto.

Paul Keller is Excellon’s Chief Operating Officer. He has over 30 years of industry experience in mining and mine development operations. He previously served as the Senior VP of Major Projects and COO of Trevali Mining. He has experience in building mines from greenfield through permitting, design and operation. Mr. Keller holds a Bachelor of Engineering – Mining from Laurentian University.

Ben Pullinger is the Senior Vice President Geology & Corporate Development for Excellon. Ben brings over 15 years of experience in advancing projects from early stage exploration through to production. Most recently, he was Vice President Exploration at Roxgold Inc., where he made a significant contribution toward growing the 55 Zone at Yaramoko Project into a producing mine. Mr. Pullinger serves on the board of Orford Mining. He is a Professional Geologist (Ontario) and holds an Honors Degree in Geology from the University of Johannesburg.

Excellon Resources Inc. (EXN), closed Friday's trading session at $2.85, up 1.7857%, on 35,902 volume with 127 trades. The average volume for the last 3 months is 43,225 and the stock's 52-week low/high is $2.19499993/$3.90000009.

Recent News

Nextech AR Solutions Corp. (CSE: NTAR) (OTCQB: NEXCF)

The QualityStocks Daily Newsletter would like to spotlight Nextech AR Solutions Corp. (CSE: NTAR) (OTCQB: NEXCF).

Nextech (CSE: NTAR) (NEO: NTAR) (OTCQB: NEXCF) (FSE: N29) today announced that it will be presenting virtually at the upcoming LD Micro Invitational XI event at 5:00 p.m. ET on Tuesday June 8, 2021. Founder and CEO Evan Gappelberg will be giving the presentation for Nextech, a leader in the rapidly growing augmented reality (“AR”) market estimated to grow from US$10.7B in 2019 to reach US$72.7B by 2024 (Markets and Markets Research). The three-day LD Micro Invitational will be held on the Sequire Virtual Events platform on June 8-10, 2021, and will feature around 180 companies, presenting for 25 minutes each, as well as several influential keynotes. Interested parties should visit https://ibn.fm/BfIaK to register for the event and watch the live presentation. To view the full press release, visit https://ibn.fm/w6Qbp

Nextech AR Solutions Corp. (CSE: NTAR) (OTCQB: NEXCF), based in Vancouver, Canada, is a leading provider of web-based augmented reality for e-commerce, advertising and virtual events, with technology ranging from simple 3D images to using 360-degree videos. Nextech AR provides businesses with a powerful end-to-end augmented reality platform designed specifically to increase online sales.

The company is currently pursuing four unique verticals with its innovative technology, including:

  • Virtual Conference Platform: Nextech’s advanced Augmented Reality and Video Learning Experience Platform for Events leverages an SaaS model to give organizations the ability to create engaging virtual event management and learning experiences. Automated closed captions and translations for over 64 languages are available. The global virtual events market was valued at $90 billion in 2020 by Grandview Research, and it’s expected to reach more than $400 billion by 2027.
  • ARitize™ for eCommerce: Launched in early 2019, the company’s SaaS platform for webAR in eCommerce serves as a ‘full funnel’ end-to-end e-commerce solution for the AR industry. The solution includes the Aritize360 app for 3D product capture, ‘Try it On’ technology for online apparel, 3D and 360-degree product views, ‘one click buy’ and much more.
  • ARitize™ 3D/AR Advertising Platform: Launched in Q1 2020, this ad platform is being marketed as the industry’s first end-to-end solution leveraging 3D asset creation for 3D/AR ads. In 2019, according to IDC, global advertising spend totaled roughly $725 billion.
  • ARitize™ Hollywood Studios: The studio is in development as a means of producing immersive content using 360-degree videos and augmented reality as primary display platforms.

Unique Marketing Strategy

Nextech AR’s efforts to disrupt the market for web-based augmented reality for e-commerce are supported by a unique go to market strategy. First, the company seeks to build or acquire platforms targeting a number of rapid growth industries, most notably AR, edTech, e-commerce, 3D/AR advertising and virtual & hybrid events.

After identifying these market opportunities, the company seeks to integrate new AR technologies into existing or novel platforms in an effort to secure market share and promote growth. These technologies include WebAR, Human Holograms, 360 Portals, ScreenAR, Genie in the bottle and AiRShow.

Nextech AR then aims to leverage these platforms to land and expand partnerships with a number of blue chip customers. The company’s current customer base includes the likes of Amazon, Johnson & Johnson, ViacomCBS, Toyota and Carnegie Mellon University.

Growth Capital

Nextech AR generates revenue through a software-as-a-service model from technology services, delivery of service revenue and sales of products through e-commerce.

As noted in its latest investor presentation, the company achieved record bookings in Q4 2020 of $7.3 million (estimated), marking a greater than 275% year-over-year increase. The company also realized greater than 235% revenue growth for calendar 2020, reporting $20 million for the 12-month period. Nextech AR attributes its 2020 increase in revenues to the contracts secured with new customers, expanded agreements with existing customers and additional conversions from e-commerce channels.

With its newly launched 3D ad network now bolstering its operations, Nextech AR is projecting revenues in excess of $50 million for 2021.

Recent Company Highlights

  • February 16, 2021: The company announced it has hired Zak Mcleod, formerly of Fastly, as its new Senior Director of Sales – EMEA. The company also announced that Rory Ganness, formerly of Salesforce.com, has joined the Nextech team as Director of Enterprise Sales – North America.
  • February 11, 2021: The company announced the launch of version 2.0 of its AiR Show app, an application that turns top music artists into interactive ‘live’ holograms, providing an immersive and engaging AR experience.
  • February 8, 2021: The company announced the launch of new standardized chat features within its Virtual Experience Platform (VXP) and recently-launched ARoom collaborative streaming solution. Nextech will also offer the chat platform as a stand-alone SaaS service externally, increasing the company’s revenue potential for 2021.
  • January 26, 2021: The company announced, in partnership with ARB Meetings and Events, it has signed a six-figure annual contract to supply its InfernoAR video conferencing and virtual events platform to NAMD.
  • January 25, 2021: The company announced that Strategic Site Selection (SSS), a 15 year old site selection leader in the meeting and events industry, has selected Nextech AR as a preferred channel partner, making Nextech’s industry leading virtual experience platform and services available to SSS clients.
  • January 20, 2021: The company announced that Microsoft’s Azure Cloud Services platform will be a standard offering across its virtual experience platforms and consumer apps, enabling hyper-scalable, secure and immersive events and applications for users.
  • January 15, 2021: The company signed a renewal agreement with Poly with an initial value of $470,000 for a six-month term and the potential for additional revenue after the six months.

Management Team

Evan Gappelberg is CEO and Founder of Nextech AR. He is an experienced operating executive specializing in creating, funding and running hyper-growth startups in both the public and private sectors. Notably, he took Take-Two Interactive Software Inc. (NASDAQ: TTWO) public with a market cap of $30 million and played a key role in guiding its growth to a current market cap of roughly $14 billion. Mr. Gappelberg has extensive experience as both a hands-on operating executive and a public markets professional.

Paul Duffy is the company’s President. He is a serial entrepreneur with over 25 years of experience in successfully starting, expanding, diversifying and selling global technology companies. Mr. Duffy is the creator of the HumaGram and inventor of the patent for Holographic Telepresence over the Internet (TOIP).

Augen Winschel is the COO of Nextech AR. He is an 18-year SAP executive with over 20 years of leadership experience in the areas of business management, business operations, marketing, product management, digital business and enterprise artificial intelligence.

Kashif Malik, CPA, CA, is the company’s CFO. He has over 15 years of financial experience spanning IPOs, M&A activity, corporate restructuring and capital raising. Mr. Malik has worked globally with public and private companies, including Merck & Company Inc. (NYSE: MRK), Real Matters Inc. (TSX: REAL) and Constellation Software Inc. (TSX: CSU). He obtained his Chartered Accountant designation while working at Deloitte.

Hareesh Acchi is the company’s President of 3D/AR Advertising. He is a 20-year Microsoft technology veteran with experience leading digital transformation and scaling businesses and enterprise organizations across the advertising industry.

Nextech AR Solutions Corp. (NEXCF), closed Friday's trading session at $2.38, up 7.2072%, on 168,719 volume with 368 trades. The average volume for the last 3 months is 243,552 and the stock's 52-week low/high is $1.50/$5.41120004.

Recent News

Healthtech Solutions Inc. (OTC: HLTT)

The QualityStocks Daily Newsletter would like to spotlight Healthtech Solutions Inc. (OTC: HLTT).

Healthtech Solutions (OTC: HLTT) is making a strong statement with its most recent acquisition. HLTT acquired Varian Biopharmaceuticals, a precision oncology company developing novel therapeutics for the treatment of cancer —and with the acquisition, the company is making its entry into the precision cancer care market (https://ibn.fm/IaAcf).

Healthtech Solutions Inc. (OTC: HLTT), through its Mediscan Inc. subsidiary, created a cloud-based software for ultrasound technology that reconstructs the analog two-dimensional grayscale visual image into a digital three-dimensional, high-definition quantifiable format.

The Mediscan software application dramatically increases the medical professional’s ability to use existing ultrasound devices at the point of care to derive meaningful data-driven clinical evaluations of a patient’s pathology or trauma, facilitate support for treatment options, monitor the patient’s ongoing progress or regress, and document compliance with required protocols and procedures. The Mediscan application also integrates with all popular EMR systems.

Healthtech Solutions Inc. acquired all of Mediscan’s capital stock in a reverse acquisition transaction on November 13, 2020. On November 23, 2020, the shareholders of Healthtech Solutions Inc. consented to a resolution changing its name to Healthtech Solutions Inc.

The company’s operational focus for the immediate future will be on Mediscan’s continuing research and development of imaging, development of other medical solutions, and making strategic investments.

Mediscan Technology

Mediscan software transforms an ultrasound analog 2D grayscale image into a digital 3D HD format. When paired with a portable ultrasound machine, the software application can enable these detailed and quantifiable scans by on-the-scene medical professionals, such primary care physicians, specialists and technical support staff, as well as sports trainers, emergency medical services (EMS) personnel, and technicians in isolation wards and emergency rooms.

Once an image has been captured in 2D, it is converted using a cloud-based software application process – a process that takes approximately one minute. The completed 3D image is viewed on the medical professional’s computer monitor, pad or smartphone at the point of service. This technique can generate 3D medical images of different organs, such as the heart, lungs, tendons, skin and nerves.

This cloud-based software application for ultrasound devices is easy to use anywhere there is an internet connection. The application provides the convenience of point of care ultrasound with the image quality of CT or X-ray and the safety of very expensive MRI technology. For patients, it provides a convenient and comfortable medical experience.

Mediscan has filed two patent applications with the United States Patent and Trademark Office, both for a System Method, Apparatus, and Computer Program Product for Ultrasonic Clinical Decision Support (https://ibn.fm/lpImS).

The technology will initially be available as medical software-as-a-service (SaaS), resulting in cost-efficiency. The SaaS model eliminates the customer’s need for external hardware and software solutions, as well as technical maintenance. The SaaS model is already widely used in the health care industry, most notably for clinical information systems and supply chain management, revenue cycle management and billing. Benefits include increased patient and physician satisfaction, lower operational costs, better workflows and more. Per company data, the Mediscan system is fast and efficient, which could generate a significant cost reduction.

Health and Wellness Applications

Mediscan’s technology has shown success in musculoskeletal (MSK), lung and cardiac imaging, enabling rapid pathology evaluation. Scanning the lung and or the MSK sub-system, the application directly images the target area, saves it as a reference, and then compares it to previous images, helping to determine if the patient is progressing or regressing.

The cardiac application combines imaging with a therapy system that detects and classifies cardiac myopathy conditions via an “entrainment” process similar to that used in treating tachycardia. This application also features a comparison function where the latest imagery is interpreted against previous vetted cardiac images to detect progression or regression.

Mediscan’s technology can also be utilized on the wellness market for diagnostics and support in a wide range of situations, such as sports injuries, physical therapy and dermatological indications.

COVID-19 Applications

COVID-19 causes complications with patients’ cardiovascular and pulmonary systems. Mediscan’s technology could help meet the growing need for advanced diagnostic and monitoring imaging at the point of care.

Portable ultrasounds equipped with Mediscan’s application are a flexible and easy-to-use solution for health care providers to evaluate, triage and diagnose COVID-19 effects on contagious patients in isolation where MRI, CT or PET Scans are not accessible. With this technology, health care providers can easily detect lung lesions or heart muscle shredding, which often appear in patients with COVID-19.

Diagnostic Imaging Market Outlook

With the increasing demand for early diagnosis and a widening scope of clinical applications, any promising technological advancements in the field constitute a significant investment opportunity. The global market is also being driven by technological advances in the diagnostic imaging industry.

As standard ultrasound 2D greyscale images are generally the norm, and 3D imaging typically requires the use of CT, PET, MRI or X-ray technology, Mediscan’s application could have a dramatic impact on the medical imaging industry, meeting the need for imaging equipment and devices that can generate human anatomy data in 3D.

The global market for diagnostic imaging was estimated at approximately $100 billion in 2016 (https://ibn.fm/xtInK) and was expected to grow steadily, creating a promising opportunity for Mediscan to distribute its technology and achieve its mission as a developer and distributor of medical imaging solutions designed for both long-term care and acute and emergency medical services.

Management Team

David Rubin is the Chairman and CEO of Healthtech Solutions Inc. Mr. Rubin has been in the financial services business for over 20 years. Concurrently, he is also the CEO of Capital Stack LLC and CEO of eProdigy Financial LLC. Rubin attended Kingsborough Community College from 1985 to 1988.

Manuel Iglesias is the President and a Director of Healthtech Solutions Inc. Mr. Iglesias has practiced law since 1980, specializing in business law, merger and acquisitions, securities and health care. Mr. Iglesias served as President, CEO and a board member of Hygea Holdings Corp., which provided primary care medical services throughout Florida and Georgia. He served as the National Chairman of the Republican National Lawyers Association in 2019 and 2020. Mr. Igleisias was awarded his MBA degree from the University of Chicago in 1981, a Juris Doctorate from the University of Chicago in 1979, and a BS in Foreign Service from Georgetown University in 1976.

Denis Kleinfeld is a Director of Healthtech Solutions Inc. and General Counsel and a Director of Mediscan Inc. Mr. Kleinfeld has extensive experience in business planning and regulatory compliance. Mr. Kleinfeld is a renowned expert in international tax and estate planning law. Kleinfeld received his Juris Doctorate from the Loyola University of Chicago School of Law in 1970.

Richard F. Parker is the Chief Research Officer of Mediscan Inc. He developed the technology that is the foundation of Mediscan’s business plan. Before he joined Mediscan, Mr. Parker was employed as an engineer and business executive for 37 years. Previously, he was President and Chief Technology Officer of CytoWave LLC. Mr. Parker was awarded a patent for technology that supported a Method and Apparatus for Generating a Therapeutic Magnetic Waveform. During the past 10 years, Mr. Parker has published 14 papers and made numerous presentations focused on magnetic imaging and treatment of sports and equine injuries. He obtained his MSEE degree from the Georgia Institute of Technology in 1971.

Healthtech Solutions Inc. (HLTT), closed Friday's trading session at $1, up 33.3333%, on 6,700 volume with 10 trades. The average volume for the last 3 months is 16,529 and the stock's 52-week low/high is $0.039799999/$4.00.

Recent News

Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF)

The QualityStocks Daily Newsletter would like to spotlight Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF).

Researchers have been studying psilocybin in an attempt to discover any benefits the substance holds that may be useful to migraine sufferers. Psilocybin is found in magic mushrooms and is the main active ingredient responsible for the psychedelic effects mushrooms produce. The findings, which were reported in “Neurotherapeutics,” offer evidence that psilocybin may provide long-lasting therapeutic benefits to individuals who suffer from migraines. Firms such as Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) that are also doing research with the objective of developing psilocybin-based medicines are likely to add to what is known about the therapeutic potential of this and other active compounds in psychedelics.

Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) is a pharmaceutical company focused on developing clinical-stage compounds for diseases with high unmet medical needs through accelerated regulatory pathways.

The company was founded in 2019 and is headquartered in San Diego, California.

Innovative Drug Pipeline

Tryp’s current focus is on advancing its two drug development platforms: its Psilocybin-for-Neuropsychiatric Disorders (PFN™) program targeting fibromyalgia, eating disorders and chronic pain conditions; and razoxane for soft tissue sarcomas. The company intends to explore opportunities to monetize these platforms after generating Phase 2b clinical data.

The company’s development plans cover three strategic initiatives:

  • Develop: Tryp intends to utilize the FDA’s 505(b)(2) regulatory pathway with available third-party preclinical data to shorten the timelines and lower the cost of its development programs.
  • Protect: Tryp plans to utilize regulatory exclusivity, patents, trade secrets and proprietary know-how to protect the commercial lifespan of its drug candidates.
  • Monetize: Tryp intends to seek out licensing, acquisition and co-development opportunities for drug candidates following their Phase 2 stages of development.

PFN™ Program

Through its PFN™ program, the company is focused on developing psilocybin-based drug therapies for certain neuropsychiatric disorders that have distinct advantages over other drugs currently on the market or in development. These advantages include:

  • Increased efficacy
  • Natural blood-brain barrier penetration
  • Enhanced safety and toxicity profiles
  • Reduced risk of abuse
  • Reduced risk of addiction

Tryp’s PFN™ program features its lead drug candidate, TRP-8802. The company’s initial indication for TRP-8802 is fibromyalgia.

Fibromyalgia is believed to be a neurosensory disorder characterized in part by abnormalities in pain processing by the central nervous system. The three drugs with FDA approval for the treatment of fibromyalgia are Pregabalin (Lyrica®), Duloxetine (Cymbalta®) and Milnacipran (Savella®), which are only effective for a portion of patients suffering from the condition.

Tryp plans to seek FDA approval to proceed directly to Phase 2 clinical trials evaluating TRP-8802 as a treatment for fibromyalgia based on existing preclinical and clinical data for the active pharmaceutical ingredients in TRP-8802.

Tryp’s pipeline of indications for TRP-8802 also includes eating disorders and certain forms of chronic pain. The company expects to initiate Phase 2a clinical trials in these areas in 2021.

Tryp recently partnered with Albany Molecular Research Inc. (“AMRI”) for the manufacture of the company’s synthetic psilocybin using proprietary methods. AMRI has initiated the process of manufacturing a 200g non-GMP demonstration batch of psilocybin and will produce a batch of GMP psilocybin in mid-2021. As the holder of the Drug Master File, Tryp expects to be the only U.S.-based manufacturer of synthetic psilocybin in the industry.

Razoxane

Tryp’s second drug candidate, TRP-1001 (razoxane), is being developed as a treatment for soft tissue sarcomas and has been evaluated in multiple Phase 2 clinical trials conducted by clinicians unaffiliated with Tryp. The company believes that existing clinical data regarding razoxane will likely allow TRP-1001 to be studied in a Phase 2 trial without the need for extensive preclinical or Phase 1 trials.

Sarcomas are rare tumors that are derived from connective tissues in the body and comprise 7% of all cancers in children. In 2018, an estimated 13,000 new cases of soft tissue sarcoma were diagnosed, with the tumors resulting in over 5,000 deaths during that year in the United States alone (https://ibn.fm/nWOGq).

Market Outlook

With its drug development programs targeting multiple indications, Tryp is well positioned to capitalize on growth opportunities spanning a range of therapeutic markets. The global oncology drugs market, in particular, represents a sizable opportunity.

In 2018, oncology indications accounted for 25% of all drug sales, representing approximately $151 billion in market revenues. By 2024, spending on oncology-targeted therapeutics is expected to top $200 billion and account for roughly 30% of total drug sales, according to a study by Cowen Equity Research (https://ibn.fm/9iZhM).

Valued at $764 million in 2020, the global fibromyalgia treatment market presents unique opportunities for development due to the limited number of approved therapies. With treatment trending upward, the market is expected to grow at a CAGR of 9.2% and reach $1.4 billion in value by 2027 (https://ibn.fm/G66e7).

Management Team

Greg McKee is the Chairman and CEO of Tryp Therapeutics. He has more than 20 years of life sciences management and venture investment experience that he brings to the company. Before taking his role at Tryp, he was the founder of Torrent Ventures, an early-stage digital health and medical technology venture fund. Mr. McKee also served as the CEO of CONNECT, the largest Southern California start-up accelerator. Before this, he was the chairman, president and CEO of then publicly traded Nventa Biopharmaceuticals, which successfully merged with Akela Pharma. Mr. McKee earned a B.A. in Economics from the University of Washington, an M.A. in International Studies from The Joseph H. Lauder Institute, and an MBA from the Wharton School at the University of Pennsylvania. He has been a member of the Young President’s Organization (YPO) since 2006.

James Gilligan, Ph.D., is the company’s President and Chief Science Officer. He has over 35 years of experience in the life sciences industry, including research and development, clinical development, international regulatory affairs and manufacturing. Before joining Tryp, Dr. Gilligan was the Co-Founder and Managing Partner of The Bracken Group, a life sciences consulting firm. He was also the Co-Founder of Unigene Laboratories, which develops technology for the recombinant manufacture of peptide hormones. Dr. Gilligan received his Ph.D. in Pharmacology from the University of Connecticut and a MSIB from Seton Hall University. He continued his post-graduate education at the Roche Institute of Molecular Biology.

Tom D’Orazio is the Chief Operating Officer of Tryp Therapeutics. He has extensive experience in leading the development and commercialization of vaccines, drugs, radiopharmaceuticals and biologics. His prior leadership experience has been in commercial planning, marketing, partnership and business development roles. He was formerly the CEO of ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA), where he led the transition from a private company to a public one. He co-founded and served as CEO of Superna Life Sciences, a specialty-pharma company focusing on niche drugs for cancer patients in Canada. Mr. D’Orazio has an MBA from Vanderbilt University with a primary focus in both finance and marketing and a B.Sc. in chemistry from Loyola University of Chicago.

Luke Hayes is the company’s Chief Financial Officer. He has played an active role in the life science industry for over 20 years with technology transfer, venture capital and finance experience. His career started with business development for Dow Chemical (NYSE: DOW), with responsibility for pharmaceutical customers such as Eli Lilly and AbbVie. Mr. Hayes has spent more than a decade doing venture capital investing while supporting companies as a director and advisor. He earned a B.S. in Chemical Engineering from Brigham Young University and an MBA from the UCLA Anderson School of Management.

Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF), closed Friday's trading session at $0.5266, up 2.7913%, on 51,577 volume with 38 trades. The average volume for the last 3 months is 73,193 and the stock's 52-week low/high is $0.449999988/$1.03999996.

Recent News

ISW Holdings Inc. (OTC: ISWH)

The QualityStocks Daily Newsletter would like to spotlight ISW Holdings Inc. (OTC: ISWH).

ISW Holdings (OTC: ISWH), a global brand management holdings company with commercial operations in telehealth and cryptocurrency mining, has seen steady growth on a year-over-year basis for the last two years. “This growth is attributed primarily to the company’s telehealth and home health care divisions,” reports a recent article. “Management believes that revenue from full-year 2021 will, at minimum, triple 2020’s topline performance with the investments that have been made in cryptocurrency mining and mining equipment.” The article quoted an excerpt from ISWH president and chairman Alonzo Pierce’s letter to shareholders wherein he noted, “We also continue to expand in our telehealth and home health care operations, which provide strong and steady cash flows as our mining segment gets up to full speed. We are focused on staying aggressive and maintaining a shareholder-friendly posture each step of the way.” To view the full article, visit https://ccw.fm/r6dbt

ISW Holdings Inc. (OTC: ISWH), through its in-house initiatives and strategic partnerships, has invested in growing operations targeting the telehealth and cryptocurrency mining industries.

The company specializes in strategic brand development and early growth facilitation. Management maneuvers its proprietary companies through critical stages of market development, including conceptualization, go-to-market strategies, engineering, product integration and distribution efficiency.

Mission

The company’s core mission is to enhance these sectors by implementing innovative services and products that are ready to meet the demands of a changing world. To that end, ISW Holdings leverages its strategic expertise, resources and innovative software to establish market-leading companies and partnerships, thereby ensuring success in their chosen industries.

Cryptocurrency Mining

The start of 2021 saw a massive resurgence in interest surrounding bitcoin and cryptocurrency mining. In mid-February, bitcoin prices hit an all-time high of greater than $57,000, and heightened demand for cryptocurrency mining power has played a key role in exacerbating a global shortage of semiconductors and computer components.

With a foothold in the cryptocurrency mining space, ISW Holdings has placed significant focus on expanding its position and capitalizing on this momentum. Recent highlights include:

  • February 9, 2021: The company announced that its revolutionary Pod5 Cryptocurrency Mining Pod will be powered up into full operational launch at the Bit5ive renewable energy cryptocurrency mining facility in Pennsylvania on February 12, 2021.
  • February 11, 2021: The company announced that it is in negotiations to purchase a large number of miners (between 300 and 900) in preparation for its coming Phase 3 expansion in mining volume.
  • February 23, 2021: The company announced its entry into a comprehensive Hosting and Maintenance Agreement prior to going online with its new ASIC s17 miners.
  • March 2, 2021: The company announced that it has successfully tripled its active cryptocurrency mining fleet with the addition of two new POD5IVE datacenters.

“As we continue to bring our miners online, we want our shareholders to be able to track the expansion and profitability of the company’s mining activity given the sharp rising trend in bitcoin prices,” Alonzo Pierce, President and Chairman of ISW Holdings, stated in a news release. “It currently costs about $11K in computing power to mine a single bitcoin. Bitcoin is pricing at over five times that level, making this is an exceptional ROI opportunity, and our responsibility to our shareholders is clear: continue to invest, expand and execute.”

Business Innovations

ISW Holdings’ diverse portfolio reflects the growing demand for essential services in a dynamic modern operational landscape. Some of the company’s current holdings and partnerships include:

  • Bit5ive LLC: ISW Holdings operates a joint venture with Bit5ive, a global leader in cryptocurrency mining. The joint-venture agreement enables ISW Holdings to collaborate with the experienced team at Bit5ive to innovate the infrastructure needed to run profitable and efficient crypto mining projects.
  • Proceso LLC: ISW Holdings has partnered with Proceso LLC to create high-density processing and mobile data centers powered by renewable energy. These innovations will allow Proceso to offer lower-cost and diverse services to its clients, including hosting and colocation services to growing sectors such as the gaming industry and cryptocurrency mining.
  • PHH Health: The company’s home health division answers the growing need for home care services in a world where health care delivery is changing and an increasingly large aging community is looking for efficient and effective ways of accessing health care.
  • Volum: The company’s logistics and supply chain management division is designed with the core goal of increasing supply chain efficiency, which is recognized as one of the key aspects of successfully growing any business.

Market Opportunity

ISW Holdings’ recent activity in the cryptocurrency mining sector has positioned it to capitalize on the forecast expansion of the cryptocurrency market in the coming years. According to data from MarketsandMarkets, the cryptocurrency space was valued at $1.03 billion in 2019 and is projected to reach $1.40 billion in 2024, achieving a CAGR of 6.18% during the forecast period.

The report suggests that major drivers for this growth will be the transparency of the underlying blockchain technology, the high volume of remittances in developing countries, the high cost of international remittance, expected fluctuations in monetary regulations and sustained investment in the cryptocurrency space by venture capital firms.

Management Team

Terry Williams is the Chief Executive Officer and Director of ISW Holdings. Mr. Williams brings to the company more than 30 years of experience in accounting and information systems, logistics, insurance and transportation. With a Bachelor’s and Master’s degree in accounting and management information systems, he amassed considerable corporate experience at UPS (NYSE: UPS), where he took several logistical roles, managing more than 2,000 employees and a budget of more than $10 billion. Mr. Williams also serves as president of Airware Transportation and Logistics and Chief Financial Officer of AVI Insurance Caribbean. In 2013, he received the National Airport Minority Advisory Council Award for mastering skills in the aviation industry.

Alonzo Pierce is the company’s President and Chairman. He brings a wealth of business development and wealth management experience to the ISW team, having spent the past 20 years building recognizable brands in multiple industry sectors. Mr. Pierce has launched enterprises in life-styled brands which were delivered to high-profile, high-net worth families and individuals. He has worked in the adult beverage industry, establishing a formidable background in marketing and brand creation. Pierce has a B.A. from Baylor University and has received multiple awards in the adult beverage industry, including ‘Outstanding Sales Performance in the Southern Region’ for Sapphire Brands. Pierce also served as a national liaison to a Super-Regional Bank’s private wealth division. In addition to his for-profit endeavors, Pierce has served on multiple charitable boards, sourcing funding for JRA, food insecure families and housing insecure families.

Kristina Mahoney-Brown is Secretary, Treasurer and Director of ISW Holdings. With more than 20 years of experience providing tax and financial consulting to real estate companies, as well as investors, developers and construction companies, Ms. Mahoney-Brown has gained solid business expertise and market knowledge and prides herself on staying abreast of the latest industry trends. Her professionalism, impeccable work ethic and advanced marketing strategies have earned her the nickname ‘The Tax Diva’. Mahoney-Brown has a Bachelor’s in accounting, a Master’s in taxation and a Master’s in business administration, specializing in personal financial planning.

ISW Holdings Inc. (ISWH), closed Friday's trading session at $0.326, up 5.3652%, on 388,320 volume with 88 trades. The average volume for the last 3 months is 872,844 and the stock's 52-week low/high is $0.0152/$1.47000002.

Recent News

Asia Broadband Inc. (OTC: AABB)

The QualityStocks Daily Newsletter would like to spotlight Asia Broadband Inc. (AABB).

Asia Broadband (OTC: AABB), a company that utilizes its specific geographic expertise, experience, and extensive industry contacts to facilitate its innovative distribution process from the production and supply of base and precious metals in Mexico to its client sales networks in Asia, recently published its Q1 2021 results, featuring positives, including a highly liquid financial position, that set a strong foundation for growth in 2021 (https://ibn.fm/1nVtj).

Asia Broadband Inc. (OTC: AABB) is a resource company focused on the production, supply and sale of precious and base metals, primarily to Asian markets.

The company utilizes its specific geographic expertise, experience and extensive industry contacts to facilitate its innovative distribution process from the production and supply of precious and base metals in Mexico to client sales networks in Asia. This vertically integrated approach to sales transactions differentiates Asia Broadband from its competitors in the mining space.

Development Program in Colima, Mexico

In October 2020, Asia Broadband announced its acquisition of a high potential mineral property in the state of Colima, Mexico. Per the press release, previous geophysics and groundwork have revealed strong indications of significant mineralization in multiple sectors of the property.

The company recently began the construction of exploration and development facilities and infrastructure roads on its Colima property, and plans are underway to extend previous geophysics and groundwork on the property. In January 2021, Asia Broadband announced its allocation of $10 million for the initial development program, with the aim of accelerating operations at the Colima site toward production.

Positioned in a major gold-iron-copper production area, the company’s Colima property is situated approximately 25 kilometers east of the Pena Colorada mine in Minatitlan, Mexico. It is advantageously located, with direct access to main Highway #3, and the property also has an essential natural water supply.

AABB Gold Token

In December 2020, Asia Broadband announced its entry into a definitive development agreement with Core State Holdings Corp., a digital assets and crypto wallet creator, to produce a white label gold-backed cryptocurrency coin. The AABB Gold token is an ERC-20 token being developed on the Ethereum blockchain.

In a February 2021 news release, the company provided a development update on the cryptocurrency token, noting that Core State Holdings Corp. “is continuing to modify the set-up and move through the final stages of testing of the iOS and Android AABB Wallet applications, including the implementation of an application interface to allow users to see the real-time exchange rate of gold that backs the price of the AABB Gold token set at one-tenth of a gram or approximately $5.80 USD.”

Core State Holdings Corp. has also continued to enhance www.AABBGoldToken.com, which the company notes will be the go-to knowledge base for all information concerning the soon-to-be launched AABB Wallet and AABB Gold token.

AABB’s primary goal for the token is to become a worldwide standard of exchange – secured and trusted with gold backing – by expanding circulation and targeting large population and high growth markets globally, including China and East Asia.

Asia Broadband Inc. (AABB), closed Friday's trading session at $0.17, up 3.0303%, on 19,913,818 volume with 2,257 trades. The average volume for the last 3 months is 48.241M and the stock's 52-week low/high is $0.0019/$0.658999979.

Recent News

Brain Scientific Inc. (OTCQB: BRSF)

The QualityStocks Daily Newsletter would like to spotlight Brain Scientific Inc. (OTCQB: BRSF).

Brain Scientific (OTCQB: BRSF), a commercial-stage medical device and software company focused on neurology, was the subject of a feature piece published by Med-Tech News, a publication covering medical devices and manufacturing. The article, authored by the marketing director of BRSF, Irina Nazarova, noted that the need for EEG devices within the pediatric segment often went unmet, even though children can suffer from a number of neurological disorders, some of which could lead to more devastating outcomes if left undetected. Further, EEG testing could be used for diagnosing ADHD, a growing market need. To view the full article, visit: https://ibn.fm/mgHzR

Brain Scientific Inc. (OTCQB: BRSF) is a commercial-stage health care company focused on developing innovative and proprietary medical devices and software. With a mission of modernizing brain diagnostics by employing cutting edge technologies to bridge the widening gap in access to quality care, the company offers two FDA-cleared products that provide next-generation solutions to the neurology market.

The company’s proprietary, clinical-grade neurological devices are supported by its intellectual property portfolio featuring patents in the United States, China and Europe.

Brain Scientific’s first commercialized devices, NeuroCap(TM) and NeuroEEG(TM), are designed to disrupt the current electroencephalogram (EEG) market by offering cost-effective and disposable substitutes to existing solutions, allowing medical professionals to collect diagnostic information quickly.

The company’s goal is to improve diagnostics by leveraging artificial intelligence and machine learning processes to analyze a database of brain readings as a method of detecting seizures and dementia. The company is also working to improve patients’ access to neurological care.

Headquartered in New York, Brain Scientific and its predecessor (and now wholly owned subsidiary, MemoryMD Inc.) was founded in 2015 and went public in 2018.

Brain Scientific’s first phase of development, from 2018 to 2019, saw the inception of portable, clinical-grade, easy-to-use neurological devices. The second phase, currently ongoing, aims to create cloud-based, secure infrastructure to transmit patient data between patients and their neurologists. The company’s third phase of development is scheduled for 2021-2022 and is expected to focus on the use of AI-assisted diagnostic analysis to increase the efficiency, consistency and accuracy of neurology specialists.

NeuroCap(TM) – Disposable EEG Headset

The NeuroCap is a disposable pre-gelled EEG headset featuring 22 electrodes and 19 active EEG channels, all adhering to the international 10-20 system. The NeuroCap was FDA-cleared in 2018. The headset can be used for recording EEGs in virtually any setting, including urban and rural emergency departments, neurology clinics, urgent care clinics, ICUs, nursing homes, assisted living facilities and remote clinical research labs.

Through a universal cable adapter, the NeuroCap is compatible with other EEG amplifiers. The cap also works in parallel with Brain Scientific’s NeuroEEG amplifier, initiating EEG studies in less than five minutes.

The company is currently seeking FDA approval for additional features for the NeuroCap, as the device has the potential to fill a gap in EEG testing availabilities during the current coronavirus pandemic: in October 2020, Brain Scientific filed an Emergency Use Authorization (EUA) application. The EUA is required for the rapid distribution of the NeuroCap device to emergency departments, intensive care units and other treatment centers to administer prescriptive EEGs safely on critically ill patients or those suspected of being diagnosed with COVID-19.

With more than 80 percent of hospitalized patients infected with COVID-19 displaying neurological symptoms, the NeuroCap could prove to be a valuable device by offering fast testing with limited contact between technicians and patients.

NeuroEEG(TM) – Miniature and Portable Wireless EEG Amplifier

The NeuroEEG is a compact, portable and affordable wireless EEG amplifier intended for prescription use. The 16-channel, FDA-cleared, clinical-grade device acquires, records, transmits and displays electrical brain activity for patients of all ages.

Both the NeuroCap and NeuroEEG are delivered by MemoryMD Inc., a wholly owned subsidiary of Brain Scientific.

Products in Active Development

Currently, Brain Scientific and MemoryMD are working on leveraging their existing products and drawing from ongoing research to develop and commercialize the next generation of solutions for the brain diagnostics market. The devices under development are being designed to address the following issues:

Routine EEG

  • NeuroCap-8 is an 8-channel EEG cap. The reduced number of electrodes is vital in emergency room situations, where the time it takes to set up the EEG is critical.

Pediatric EEG

  • NeuroCap Pediatric is positioned to become the first disposable and pre-gelled headset available for the pediatric market.

Long-Term Monitoring

  • NeuroCap LTM for adult and pediatric patients is a disposable cap designed to monitor rhythmic and periodic patterns for up to 72 hours, providing essential diagnostic capabilities.
  • NeuroEEG 24 Channel Amplifier is a portable and wireless amplifier with over 24 hours of battery life.

Artificial Intelligence

  • Brain E-Tattoo is a minimally invasive four-channel EEG electrode designed for long-term monitoring.
  • An AI database of brain biomarkers collects data on both normal and abnormal brain data to detect neurological diseases. The goal is for machine learning algorithms to enhance understanding of brain-behavior related to epilepsy, memory dementia and pre-Alzheimer’s diagnostics.

Telemedicine

Brain Scientific is expanding the vision for telemedicine in neurology. The company aims to address the current acute neurologist shortfall (20 states have less than 10 neurologists per 10,000 patients) through the use of teleneurology.

Partnership with Marketing Brainology

Brain Scientific has a longstanding partnership with Marketing Brainology, a neuromarketing firm using neuroscience approaches to understand consumer behavior. In 2019, Marketing Brainology conducted a study using NeuroCap and NeuroEEG to determine the most effective Super Bowl commercials.

“Thanks to Brain Scientific’s NeuroCap and NeuroEEG, we are able to better understand the art and science of the human decision-making process,” Michelle Adams, Ph.D, Founder of Marketing Brainology, stated in a news release.

In April 2020, Marketing Brainology again conducted a study leveraging Brain Scientific’s disposable EEG cap to determine how brains were reacting to COVID-19 messaging. Subjects were presented with multiple media impressions, and Marketing Brainology analyzed their responsive biomarkers. The results identified the most effective messaging for engaging with an audience during a crisis.

Market Outlook

The current global market for EEG devices is estimated at $956.1 million. It is expected to rise with a CAGR of 8.7% from 2019 to 2026, reaching $1.6 billion in value by 2026, according to Grandview Research.

In total, there are approximately 6,150 hospitals in the U.S., according to the American Hospital Association. Critically, though, just 254 of those hospitals are certified Level 4 Epilepsy centers with 24/7 EEG coverage. Since very few non-Level 4 centers have extensive EEG tech coverage, this creates a significant opportunity for Brain Scientific to bridge the gap by providing over 5,900 hospitals with lower cost amplifiers and disposable EEG caps.

The company also see opportunities to work with other businesses, such as EEG manufacturers hoping to package Brain Scientific’s solutions with their products, which could greatly expand Brain Scientific’s addressable target market.

Management Team

Dr. Baruch “Boris” Goldstein, Ph.D., is co-founder and Chairman of Brain Scientific. He is a seasoned executive with a proven talent for aligning global business strategies with established and emerging management teams. Goldstein’s growth-focused leadership style has helped him raise over $750 million in venture capital for the development of innovative companies and startups in diverse industries, including financial services, biomedicine, alternate energy and new materials, as well as groundbreaking work in artificial intelligence. His recent achievements include important advancements in neurology and unlocking the potential of AI correlations and machine learning applied to life sciences and medical research. He built a suite of first-to-market companies as a technology-oriented leader, including Ryah Medtech, Brain Scientific, GrapheneCA, E-Forex and Intelligent Video Systems. He also co-founded BrainRX, a company specializing in pre-Alzheimer’s diagnostics.

Dr. Nikolay Kukekov, Ph.D., is a Director of Brain Scientific and a partner at HRA Capital. Before joining HRA Capital, Kukekov was Managing Director of Healthcare Investment Banking at Summer Street Research. His scientific background includes a bachelor’s degree in Molecular, Cellular and Developmental Biology from the University of Colorado at Boulder. He earned his Ph.D. in neuroscience from Columbia University – College of Physicians and Surgeons in New York.

Stuart Bernstein is the company’s Vice President of Marketing. He was recently named to the role after spending the first part of his professional career in senior technical management roles with Fortune 500 companies such as NCR (NYSE: NCR), IBM (NYSE: IBM) and Control Data Corp. He was the CEO of BioSignal, an EEG medical device company. He is also a co-founder of several software engineering and telemedicine firms. One of them, Brain Saving Technology, is now Specialist on Call (SOC Telemed) – a leading telemedicine company that powers over 850 facilities for teleneurology, telepsychiatry and critical care telemedicine with over 200 physicians.

Brain Scientific Inc. (OTCQB: BRSF), closed Friday's trading session at $0.77, off by 3.7259%, on 5,740 volume with 4 trades. The average volume for the last 3 months is 8,765 and the stock's 52-week low/high is $0.116099998/$2.29999995.

Recent News

Imagin Medical Inc. (CSE: IME) (OTCQB: IMEXF)

The QualityStocks Daily Newsletter would like to spotlight Imagin Medical Inc. (CSE: IME) (OTCQB: IMEXF).

Bladder cancer has a one of the highest recurrence rates, with approximately 50% of patients likely to relapse, making it one of the most prevalent and expensive cancers to treat. A primary contributor to this high recurrence rate is the difficulty surgeons may have in seeing and clearly locating all of the cancerous tumors and their margins. If cancerous cells are missed and not removed, the cancer can recur. That’s what makes Imagin Medical’s (CSE: IME) (OTCQB: IMEXF) patented i/Blue Imaging System(TM) so important. It will directly address this problem by displaying real-time white and blue light images simultaneously, side-by-side, removing the challenge of constantly switching and reorienting. The surgeon will see the bladder wall alongside the cancerous cells, making navigation far easier and more accurate and, overcoming the primary weakness of the traditional BLC system. In addition, unlike current BLC technology the i/Blue Imaging System will adapt to most endoscopes on the market.  

Imagin Medical Inc. (CSE: IME) (OTCQB: IMEXF) is a surgical imaging company focused on establishing a new standard of care in visualizing cancer during minimally invasive procedures. Its initial focus is on bladder cancer.

The company’s first product is the i/Blue Imaging™ System, based on advanced optics and light sensors and employing patented ultrasensitive imaging technology. Imagin Medical believes the system can significantly improve surgeons’ ability to visualize and remove cancer cells.

Founded in 2016 and headquartered in Boston, Massachusetts, the company works to enhance its market potential by expanding its technology to multiple endoscopic indications, such as laparoscopic, colorectal and thoracic procedures, accommodating multiple contrast agents and illumination sources.

i/Blue Imaging™ System

The conventional method used for visualizing bladder cancer during surgery is an endoscopic procedure called a cystoscopy. This procedure uses white light to illuminate the bladder. White light has been used for decades and is the standard for more than 90% of the market. Blue light cystoscopy uses blue-filtered white light, which addresses the limitations of white light (such as detecting flat tumors and the fine edges that may result in cancerous cells being left behind during removal).

Blue light uses a contrast agent that causes cancer cells to fluoresce when illuminated. Surgeons are then able to more effectively visualize and resect the margins of bladder tumors to reduce the risk of recurrence. Notably, the use of the white light is still necessary during a blue-light procedure so that the surgeon can orient their position within the bladder.

Imagin Medical’s i/Blue Imaging System addresses the limitations of both white and blue light cystoscopies. The i/Blue System combines the white and blue light with an FDA-approved imaging agent and simultaneously displays side-by-side images in real-time, without the necessity to switch back and forth between the two images.

The i/Blue Imaging System is unlike other methods available on the market today. It is external to the body and can attach to almost any endoscope model currently in use. This way, hospitals adopting Imagin Medical’s technology have the ability to use their current endoscopes without the need to purchase new equipment.

Bladder Cancer Prevalence

The company’s initial focus is bladder cancer, which is the sixth most prevalent form of cancer in the United States. In 2020, the number of new bladder cancer cases is expected to total 81,400, accounting for 4.5 percent of all new cancers diagnosed. The death rate in 2020 for cancer deaths associated with the bladder is forecast at 17,980, or 3% of all cancer-related deaths (https://ibn.fm/qLi3l).

Bladder cancer also has one of the highest recurrence rates among all forms of cancer, leaving about 600,000 people in fear that their cancer will return, according to Imagin Medical. The company is committed to addressing this issue, and i/Blue demonstrations have indicated that the use of both white and blue light can enhance accuracy of detection and removal of cancer cells, potentially lowering recurrence rates.

Based on Verified Market Research, the global bladder cancer research market was valued at $3.43 billion in 2018. It is estimated to grow with a CAGR of 4.03% through 2026, resulting in a projected $4.71 billion market (https://ibn.fm/rI7G6).

Management Team

E. James Hutchens is the Chief Executive Officer of Imagin Medical Inc. He is a proven entrepreneur with over 30 years of experience in management in the medical technology industry. Hutchens served as a managing partner with Origin Partners, a $55 million early-stage venture capital fund. He was also the founder and CEO of both Microsurge Inc. (a venture-backed minimally invasive surgical company) and Choice Therapeutics (an advanced wound-care company). He is a former member of the Board of Directors of the Brigham and Women’s and Faulkner hospitals. Hutchins holds a BS in Business Administration from Boston University.

John Vacha is the company’s Chief Financial Officer. He has 20 years of experience in the health care industry. Prior to Medtronic’s acquisition of Intact Medical Corp. in 2017, Vacha was the company’s President, CEO and a board member for seven years. He is a licensed CPA in Massachusetts. Vacha has an MBA and an MS in Accounting from Northeastern University in Boston. He is also a serving member of the Board of Directors at the South Boston Health Center. He currently has two patents in electrosurgical instrumentation.

Michael G. Vergano is the Director of Operations of Imagin Medical. He has been the President of The Harvest Group Inc. since 1998, where he has provided consultant services for startups and major corporations. Vergano has over 30 years of experience in the medical device industry. He has held management positions at Microsurge Inc., Ciba Corning Diagnostics and Boston Scientific Corp. He is currently the holder of 11 medical device patents and holds a BS in Mechanical Engineering from Tufts University.

Pam Papineau is the company’s Director of Regulatory Affairs. She has over 30 years of experience in quality and regulatory affairs with Boston Scientific, Baxter and Cogentix. She has served as a consultant on various devices including imaging, endoscopy, orthopedic, GI/GU and cardiovascular applications. Papineau has successfully prepared dozens of FDA pre-market and EU submissions to support CE marking of a broad spectrum of medical devices. She is an ASQ Certified Quality Engineer, a Certified Biomedical Auditor, a Certified Quality Auditor and an ISO 13485:2016 Lead Auditor, and she is certified by the Regulatory Affairs Professional Society – U.S., EU and Canada. Papineau works with the company’s legal counsel to prepare pre-submission meetings with the FDA and activities through the regulatory approval process.

Imagin Medical Inc. (CSE: IME) (OTCQB: IMEXF), closed Friday's trading session at $0.461, off by 3.6573%, on 20,672 volume with 5 trades. The average volume for the last 3 months is 9,604 and the stock's 52-week low/high is $0.200000002/$1.16999995.

Recent News

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


The QualityStocks Sponsored News


The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


QualityStocksTwits

QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal


The QualityStocks Sponsored News


The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


QualityStocksTwits

QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal


The QualityStocks Sponsored News


The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.